Nurses Revision

nursesrevision@gmail.com

Erectile dysfunction medications

Erectile Dysfunction Medications

Erectile Dysfunction

Erectile dysfunction, ED is the inability of the male to attain and maintain an erection sufficient to permit satisfactory sexual intercourse.

Penile erectile dysfunction is a condition in which the corpus cavernosum does not fill with blood to allow for penile erection. This can result from the aging process and in vascular and neurological conditions.

So, what is impotence?

Impotence, a term often used synonymously with ED, many involve a total inability to achieve erection, an inconsistent ability to achieve or ability to sustain only brief erections.

Physiology of an Erection

This begins with stimulus such as sight and touch. This stimulates the parasympathetic nervous division that transmits nerve impulses to the erectile tissue of the penis (corpus carvernosum). The nerve endings release nitric oxide(NO) which binds on muscle cells in the penis leading to generation of cyclic GMP (Cyclic Guanosine monophosphate) which relaxes the muscle cells in the corpus cavernosum leading to creation of larger intracellular spaces and sinusoids. More blood flows into the erectile tissues, the tissue expands compresses the veins leaving the penis, thus increased blood volume in the organ and one erects.

      Erection is continuously maintained during sexual intercourse by the release of NO, and prostaglandin E1 (PGE1).

Termination of erection( Detumescence ) is brought about by 2 events i.e.

  • Activity of enzyme phosphodiesterase type 5 enzyme (PDE-5) which catalyzes the breakdown of GMP into inactive form.
  • Stimulation of sympathetic nervous division to bring about the contraction of the penile muscles terminating ejaculation.

 

Pharmacology application of the above;

  • Erection relies on the penile blood flow thus an event that interferes with penile blood flow results into penile dysfunction.
  • Any factor which interferes with neuro-transmitters such as acetylcholine may end with Erectile Dysfunction.
  • Psychological factors e.g. stress may as well interfere initiation of erection.

Classification of Erectile Dysfunction.

Primary Erectile Dysfunction; is where a man has never  been able to attain and maintain an erection for sexual intercourse

Secondary Erectile Dysfunction: is where impotence occurs in a man who has past history of satisfactory sexual performance.

Causes of Erectile Dysfunction

  • Erectile Dysfunction mainly occurs past middle age and is common after the age of 65 years.

A variety of vascular, Neurological, hormonal or endocrinal, pharmacological or psychological and genetic causes may underly the disorder, i.e.

  • Vascular diseases: Blood supply to the penis can become blocked or narrowed as a result of vascular disease such as atherosclerosis (hardening of the arteries).
  • Neurological disorders (such as multiple sclerosis): Nerves that send impulses to the penis can become damaged from stroke, diabetes, or other causes.
  • Psychological states: These include stress, depression, lack of stimulus from the brain and performance anxiety.
  • Trauma: An injury could contribute to symptoms of Erectile Dysfunction.
  • Cancer treatments;  near the pelvis can affect the penis’ functionality.
    Surgery and or radiation for cancers in the lower abdomen or pelvis can cause Erectile dysfunction. Treating prostate, colon-rectal or bladder cancer often leaves men with Erectile dysfunction.
  • Drugs;  used to treat other health problems can negatively impact erections such as Cimetidine (Tagamet), Ranitidine (Zantac)

Classification of Drugs used to treat Erectile Dysfunction.

There are divided into 4 groups;

  • Central inhibitors
  • Peripheral inhibitors
  • Central conditioners
  • Peripheral conditioners

PDE 5 Inhibitors/Peripheral Inhibitors.

These are agents which act in the penile tissue to maintain the environment of erection. They include phosphodiesterase-5 inhibitors e.g. sildenafil, tadalafil, and vardenafil are selective PDE-5 inhibitors developed drugs in the past decade and found effective in a majority of patients with Erectile Dysfunction.

SILDENAFIL:

 It is an orally active drug

Classification:

Therapeutic– ED agent, vasodilator

Pharmacological– phosphodiesterase type 5 inhibitor

Brand names:
  • Kamagra
  • Penegra
  • viagra
  • Caverta
  • Edegra 25, 50, 100mg tablets
Indications:         
  • Erectile Dysfunction
  • Pulmonary Hypertension.
Mechanism of action;

 Sildenafil acts by selectively inhibiting an enzyme phosphodiesterase-5 and enhancing nitric oxide action in corpus cavernosum thus preventing the breakdown of GMP produces smooth muscle relaxation of the corpus cavernosum which in turn promotes increased blood flow and subsequent erection hence sex intercourse and exercise tolerance is improved but it has no effect on penile (swelling) tumescence in the absence of sexual activity. It doesn’t cause priapism in most patient.

 Dosage:

  It is recommended in the dose of

  • 50mg for men less than 65 years,
  • elderly 25mg if not effective then 100mg 1 hour by intercourse.

Duration and degree of penile erection is increased in 74-82% of men with Erectile Dysfunction including diabetic Neuropathy cases.

However, Sildenafil is effective in men who have lost libido or when ED is due to spinal cord injury or damaged Nervic eregantis since Nitric Oxide is an important regulator of pulmonary vascular resistance, PDE-5 inhibitor lower pulmonary circulation than vardenafil and is only PDE-5 inhibitor shown to improve arterial   oxygenation in pulmonary Hypertension. It has now become the drug of choice for this condition

N.B.; it should be given once a day.  

Adverse effects/ side effects:

These are mainly due to preservation of nitric oxide which causes vasodilatation in the brain.

  • Dizziness and headache
  • Nasal congestion
  • Hypotension and palpitation
  • Loose emotion
  • A feeling of dependency/ addiction
  • Flushing
  • Tachycardia
  • Muscle pain
  • Diarrhoea
  • Sildenafil in addiction, weakly inhibits the isoenzyme PDE-5 which is involved in photoreceptor transduction in the retina. As such impairment of colour vision especially, blue-green discrimination occurs in some recipients.
  • Hormones and related drug neuropathy among users of PDE-5 inhibitors have be reported.
Contraindications:
  • In patients with coronary heart diseases.
  • Those taking nitrates. Though sildenafil remains effective for less than 2hours, it is advised that nitrates should be avoided for 24hours
  • Presence of liver or kidney disorder
  • Peptic ulcer, bleeding disorder
  • Patients of leukemia, sickle cell anemia, myocardial infarction etc.
Drug interactions:
  •  Sildenafil markedly potentiates the vasodilator action of nitrates, precipitates fall in Blood Pressure and myocardial infarction may occur.
  • Inhibitors of CYP3A4 like erythromycin, Ketoconazote, cemetidine may potentiate its action i.e. may increase Sildenafil plasma concentration.
  • Vitamin k antagonist may increase the risk of bleeding.
  • Concomitant use with alpha- blockers may lead to hypotension.

N.B: men even without Erectile Dysfunction are going for it to enhance sexual satisfaction.

Nursing implications:
  • Determine Erectile Dysfunction before administration.
  • Monitor hemodynamic parameters and exercise before and after therapy
Patient/ family teaching:
  • Instruct the patient to take drugs at least 1 hour before sexual activity
  • Not more than once a day.
  • Instruct the patient that sexual stimulation is required for erection to occur.
  • Advise the patient that the drug is not indicated for women.
  • Advise the patient not to concurrently take the drug with nitrates or alpha-adrenergic blockers
  • Instruct the patient if chest pain occurs after taking the drug to report to the PHC practioners immediately.
  • Advise the patient to avoid excess alcohol intake in combination with PDE-5 since it can increase the risk of orthostatic hypotension
TADALAFIL:
  Brand names;
  • Megalis,
  • Tadarich,
  • Tadalis,
  • Cialis and Apcalis 10, 20mg tablets

            It is a more potent and longer acting congener of Sildenafil, duration of action is 24-36 hours. It is claimed to act faster, though peak plasma levels are attained between 30-120minutes.

Indication;
  • Erectile Dysfunction
Mechanism of action
  • As for Sildenafil

Side effects, risks, contraindications and drug interactions are similar to Sildenafil

  • Because of its longer lasting action, nitrates are contraindicated for 36-48hours after Tadalafil.
  • Due to its lower affinity for PDE-6, visual disturbances occur less frequently
Dosage:
  •  10mg o.d. at least 30minutes before sexual intercourse (max 20mg)

Peripheral Initiators of Erection

They include Alprostadil administered intra cavernously (injected) directly into the corpus cavernosum using a fine needle or introduced into the urethra as a small pellet, produces erection in few hours to permit intercourse  .  It is more used in patients taking anti-hypertensive drugs, those with cardiac diseases e.g Coronary artery disease and patients who do not respond to PDE-5 inhibitors.

Mode of Action

It is a prostaglandin E1 analog thus relaxes the penile muscles bringing about erection.

Contraindications
  1.  Presence of any anatomical obstruction or condition that might predispose to priapism. The risk could be exacerbated by these drugs.
  2.  Penile implants.
  3.  Bleeding disorders, CV diseases, optic neuropathy, severe hepatic and renal disorders.
Adverse effects
  • Priapism
  • Thrombo-embolism
  • Local tenderness
  • Penile fibrosis

Central initiators:

 These initiate neuronal path ways for erection e.g.

  • Apomorphine administered orally
Mechanism of action:

Apomorphine is a dopamine agonist  which acts centrally to stimulate an erectile neuronal path way.

It is also for known for Parkinsonism and induction of vomiting thus rarely used for this indication

Adverse effect:
  • Nausea and vomiting
  • Head ache and dizziness
  • Decreased milk production if taken by lactating mothers for another use

Central conditioners:

These provide a central mood condition of erection. They include;

(a). Trazodone which is a CNS anti-depressant due to massive adverse effects

(b). Androgens: e.g. testosterone

Click here to read more about Androgens.

Erectile Dysfunction Medications Read More »

androgens

Androgens

Androgens

Androgens are male sex hormones

Androgens include Testosterone, which is produced in the testes, and the Androgens, which are produced in the Adrenal glands.

Androgens are chiefly produced in the testes and small amounts in adrenal cortex. In female, small amounts are produced in the ovary and adrenal cortex.

        Testosterone is the most important natural androgen and in adult male, 8-10mg is produced daily. Its secretion is regulated by gonadotropins and gonadotrophic releasing Hormone (GnRH).  Inadequate production of androgens is due to pituitary malfunction or atrophy, injury to or removal of testicles. Androgens stimulate the development of male characteristics.

Naturally occurring androgens hormones are;

  • Testosterone, the principal androgenic hormone produced by the leydig cells of the testes.
  • Dehydroepiandrosterone (DHEA) produced by adrenal cortex.

Common Terms

Anabolic steroids: androgens developed with more anabolic or protein-building effects than androgenic effects.
Androgenic effects: effects associated with development of male sexual characteristics and secondary characteristics (e.g., deepening of voice, hair distribution, genital development, acne)
Androgens: male sex hormones, primarily testosterone; produced in the testes and adrenal glands
Hirsutism: hair distribution associated with male secondary sex characteristics (e.g., increased hair on trunk, arms, legs, face)
Hypogonadism: underdevelopment of the gonads (testes in the male)
Penile Erectile Dysfunction: condition in which the corpus cavernosum does not fill with blood to allow for penile erection; can be related to aging or to neurological or vascular conditions

Examples of Androgens

Drug NameUsual DosageUsual Indications
danazol (Danocrine)100–600 mg/d PO, depending on use and responsePrevent ovulation for treatment of endometriosis; prevention of hereditary angioedema
fluoxymesterone (Androxy)5–20 mg/d PO for replacement therapy; 10–40 mg/d PO for certain breast cancersTreatment of delayed puberty in male patients and certain breast cancers in postmenopausal women
testosterone (Androderm, Depo-testosterone)50–400 mg IM every 2–4 weeks, dose varies with preparation (check more below)Replacement therapy in hypogonadism (check more below)
methyltestosterone (Testred, Virilon)Males: 10–50 mg/d PO Females: 50–200 mg/d POReplacement therapy in hypogonadism; treatment of delayed puberty in male patients and certain breast cancers in postmenopausal women

TESTOSTERONE (depo-testerone, androderm) 

Classification:

Therapeutic: Hormone

Pharmacological: Androgen

Pregnancy; Category-x

Schedule: III controlled substance.

Dosage: 50–400 mg IM every 2–4 weeks, dose varies with preparation; some long-acting depository forms are available; dermatological patch 4–6 mg/day, replace patch daily.

Effects of Testosterones.

Anabolic Effects (Growth and Metabolic Functions)

  • Maintains bone density.
  • Regulates fat distribution.
  • Helps in Red Blood Cell production.
  • Supports muscle growth, strength and body mass.
  • Speeds up recovery from injury.
  • They act to increase the retention of nitrogen, sodium, potassium, and phosphorus.
  • They decrease the urinary excretion of calcium.
  • Testosterones increase protein anabolism and
    decrease protein catabolism (breakdown).

Androgenic Effects ( Sexual Characteristics and Functions)

  • Enhances sex drive and libido.
  • Increases aggression.
  • Acne.
  • Beard and body hair.
  • Male pattern boldness.
  • Development and maintenance of male sex organs.
  • Spermatogenesis.
  • Increased size of the prostate.

Control of Testosterone Secretion.

Hypothalamus releases GnRH, which stimulates the Anterior Pituitary gland to secrete FSH an LH which in turn stimulate the Leydig cells to secrete testosterone. High levels of serum testosterone exerts a negative feedback i.e.

  • APG suppresses secretion of LH.
  • Hypothalamus suppresses the GnRH.

Indications of Testosterone.

  1. Hypogonadism and impotence in males due to testicular/pituitary/hypothalamic deficiency.
  2. Testosterone deficiency .
  3. Breast cancer treatment in post menopausal women, who cant be operated.
  4. Treatment of delayed male puberty.
  5. Prevention of postpartum breast engorgement.
  6. Illegally, sportsmen often use anabolic steroids for promoting their musculature and sporting abilities.
  7. Blockage of follicle-stimulating hormone and luteinizing
    response hormone release in women to prevent ovulation for
    treatment of endometriosis.
  8. Prevention of hereditary angioedema

Contraindications of Testosterone.

  •  Allergy to androgens or other ingredients in the drug. Prevent hypersensitivity reactions.
  •  Pregnancy, lactation. Potential adverse effects on the neonate. It is not clear whether androgens enter breast milk.
  •  Presence or history of prostate or breast cancer . Aggravated by the testosterone effects of the drug.
  •  Liver dysfunction, Cardiovascular disease. Can be exacerbated by the effects of the hormones.
  •  Topical forms of testosterone have a Black Box Warning alerting user to the risk of virilization (Female develops male characteristics) in children who come in contact with the drug.
  •  Danazol has Black Box warning regarding the risk of thromboembolic events, fetal abnormalities, hepatitis, and intracranial hypertension.
  • For use with caution in patients with Diabetes Mellitus, BPH and Sleep apnea.

Side Effects and Adverse Effects of Testosterone

                      In men,

  • Administration of an androgen may result in breast enlargement
  • (gynecomastia),
  • testicular atrophy,
  • inhibition of testicular function,
  • impotence,
  • enlargement of the penis,
  • nausea and vomiting,
  • jaundice,
  • headache,
  • anxiety,
  • male pattern baldness,
  • acne and depression,
  • fatigue,
  • abdominal cramps,
  • confusion,
  • deepening of the voice,
  • edema,
  • drug-induced hepatitis,
  • gingivitis.
  • hirsutism (increased hair distribution)

                         In women,

  • receiving an androgen preparation for breast carcinoma the most common adverse reactions are;
  • amenorrhea and virilization (acquisition of male sexual characteristics such as changes in body and facial hair, a deepening voice, acne, menstrual irregularities and enlargement of the clitoris).
Drug Interactions
  1. May increase action of warfarin (anti-coagulants),  oral hypoglycemic agents and insulin.

  2.  Concurrent use with corticosteroids may increase the risk of edema formation.

Nursing intervention/ involvement:

  •  If the androgen is to be administered as a buccal tablet, the nurse demonstrates the placement of the tablet and warns the patient not to swallow the tablet but to allow it to dissolve in the mouth.
  • The nurse reminds the patient not to smoke or drink water until the tablets is dissolved. Oral and parenteral androgens are often taken or given by injection outpatient basis.
  • When given by injection, the injection is administered deep I.M into the gluteus muscle.
  •   Oral testosterone is given with or before meal to decrease gastric upset.
  • When testosterone Trans -dermal system testostederm is prescribed, the nurse places the system on clean, dry scrotal skin. Optimal skin contact of the Trans dermal system is achieved by shaving scrotal hair before placing the system.
  • Monitor fluid input and output
  • Weigh the patient twice a week
  • Assess for edema and report
  • Monitor secondary sexual characteristics in men
  •  Monitor menstrual irregularities, deepening of the voice, in females.
  • Monitor Hemoglobin and hematocrit periodically
  • Monitor urine and serum calcium levels
Patient/family teaching:
  1.  Advise the patient to report signs of priapism, difficulty in urinating, hypercalcemia, edema, unexpected weight gain, swelling of the fee, hepatitis, unusual bleeding.
  2. Explain rationale for prohibiting use of testosterone for increasing athletic performance
  3.   Notify Doctor of pregnancy.
  4.   DM patients to monitor blood sugar.
  5. Regular follow up, laboratory tests and physical examination
  6.  For ladies to notify doctor if signs of body hair distribution, deepening of voice menstrual irregularities occur.

ANABOLIC STEROIDS

 These are agents that are not easily converted to the potent androgen 5 alpha o-dihydrotestosterone (DHT) hence their effects on sex are less but their anabolic effect are high.

Drugs commonly used by athletes include; nandolone, stanozolol, and mithenelone. All of this drugs are regulated as controlled substances, making their use by athletes illegal.

Clinical uses/indications of anabolic steroids.

  • Osteoporosis
  • Appetite improves and there is a feeling of well being.
  • To counteract osteoporosis seen in chronic glucocorticosteroid therapy.
  • Stimulates linear growth in prepubertal boys (height).
  • Used in renal diseases.
NANDROLONE

      This is another steroid naturally produced by body, it is often synthesized and sold under the trade names Deca- Durabolin and Durbolin.

Professional athletes like Berry Bonds and Roger Clemens alleged used nandrolone to illegally enhance their performance.

STANOZOLOL:

       This synthetic steroid goes by the brand name Winstrol. This steroid is unusual in that it can be taken orally. Base ball players like Rafael. Palmeiro have tested positive for illegal use of stanozolol and strength athletes often use it illegally to quickly get stronger.

OXANDROLONE:

          Is a synthetic steroid retailed as the drug Anavar, which is approved for use in osteoporosis. Body builders use this steroid illegally to create greater muscle.

Contraindications:

  • Male patients with cancer of the breast or with known or suspected carcinoma of the prostate.
  • Carcinoma of the breast in female with hypercalcemia; androgenic anabolic steroids may stimulate osteolytic resorption of bones.
  • Pregnant because of masculinization of the fetus.
  • Nephrosis or the nephritic phase of nephritis.

Side effects of anabolic steroids:

  • Severe acne, oily skin and hair – hair loss.(virilization)
  • Liver diseases resulting into complications such as heart attack and stroke.
  • Altered mood, irritability, increased aggression, depression or suicidal tendencies.
  • Alteration in cholesterol and other blood lipids
  • High blood pressure
  • Gynecomastia- abnormal development of mammary glands in men causing breast enlargement.
  • Shrinking of testicles.
  • Azoospermia (absence of sperm in semen)
  • Menstrual irregularities in women
  • Infertility
  • Excess facial or body hair, deeper voice in women.
  • Stunted growth and heat in teens
    risk of viral or bacterial un function due to unsterile injections
  • Edema
  • Prostate cancer
  • Injury from skin-to-skin transfer of topical testosterone

 

Drug interactions:

  • Anti-coagulants. Anabolic steroids may increase sensitivity to oral anti-coagulants. Dosage of the anti-coagulants may have to be decreased in order to maintain the prothrombin time at the desired therapeutic level. Patients receiving oral anti-coagulant therapy require close monitoring, especially when anabolic steroids are started or stopped.

Patient’s information:

  • The physician should instruct patients to report any of the following effects of androgenic anabolic steroids,
  • hoarseness,
  • acne,
  • changes in menstrual periods,
  • more hair on the face,
  • Nausea and vomiting,
  • changes in skin colour or ankle swelling.

ANTI ANDROGENS

Antiandrogens, also known as androgen antagonists or testosterone blockers, are a class of drugs that prevent androgens  from mediating their biological effects in the body.

They act by blocking the androgen receptor and/or inhibiting or suppressing androgen production. They include:

  • Danzol
  • Finasteride
  • Spironolactone
  • Flutamide
  • Cyproterone
  • Ketoconazote
  • Bicalutamide and Nilutamide

Finasteride

Available preparations:      Tablets 5mg

Available brands:                 Finest, Proscar

           The androgen hormone inhibitor finasteride is a synthetic drug that inhibits the conversion of testosterone into the  androgen 5 alpha o-dihydrotestosterone (DHT). The development of the prostate glands is dependent on DHT. The lowering of serum levels of DHT reduces the effect of this hormone on the prostate gland, resulting in decrease in the size of the gland and this synthesis associated with prostate gland enlargement.

Indications;

  • Benign Prostatic Hyperplasia(BPH)
  • Androgenetic alopecia (male pattern baldness) in men only

Mechanism of action:

 It inhibits the enzyme 5-alpha-reductase which is responsible for converting testosterone to its potent metabolite 5-alpha dihydrotestosterone in prostate, liver and skin since 5-alphs dihydrotestosterone is partially responsible for prostatic hyperpiesia and hair loss.

Dose:

  • In BPH 5mg o.d
  • Alopecia 1mg/day for 3 months or more. Available in tablets of mg and 5mg

Side effects;

  • Decreased libido
  • Decreased volume of ejaculation
  • Erectile dysfunction/impotence
  • Breast tenderness and enlargement
  • Testicular pain

Contraindications/precautions;

  • Known hypersensitivity to finasteride
  • Use with caution on hepatic impairment

Nursing implications:

  •   Assess for symptoms of prostatic hyperplasia e.g. feeling of incomplete bladder emptying, interruption of the urinary stream
  •   Digital rectal examination should be done before and periodically during BPH therapy.
  •   Laboratory tests of prostate specific antigen cancer concentration which is used to screen for cancer of prostate.
  • Take this drug without regard to meals.

Patient/ family teaching;

  1. Finasteride possesses risk to male fetus; tell males not to have sex with pregnant women to avoid the risk of absorption
  2. Inform the Doctor immediately if sexual partner is or may become pregnant because additional measures such as discontinuing the drug or use of condom may be necessary.

Androgens Read More »

Uterine Relaxants

Uterine Relaxants

Uterine Relaxants

Uterine Relaxants are drugs which inhibit uterine motility by decreasing the frequency and strength of contractions.

Uterine Relaxants are drugs that inhibit uterine contractions and prolong pregnancy to allow the fetus develop more fully, thereby increasing the chances of neonatal survival.

These drugs prevent premature labor. It can succeed if only the cervical dilatation is less than 4cm.
They include;

  • Salbutamol
  • Magnesium Sulphate
  • Nifedipine
  • Indomethacin
  • Terbutaline

SALBUTAMOL

Legal class; class B controlled drugs
Medical class; tocolysis
Form; tabs , sterile solution for injection
Dosage :tabs 4mg
Soluton for injection 50mg/ ml

Indications
  • Uncomplicated premature labour between 24 to 33 weeks of gestation
  • Asthma
Contraindications
  •  Cardiac diseases
  • APH
  • Intra uterine fetal death.
  • Intra uterine infections
  • Raptured membranes
  • Eclampsia and pre-eclampsia
  • 1st an 2nd trimester of pregnancy
Dose
  • For premature labour, intravenous, infusion 10mcg/ min, gradually increase according to response at 10 minutes intervals until contractions diminish, then increase rate until contractions have ceased, max dose : 45mcg/min
  • Maintain rate for 1hr then gradually reduce by intravenous or intramuscular injection 100-250mg repeated according to response, then orally 4mg every 6-8hrs
    Do not use for more than 48minutes
Side effects
  •  Hypoglycemia
  • Vomiting and nausea
  • Sweating
  • Tremors
  • Hypotension
  • Pulmonary oedema
  • Maternal and fetal tachycardia
  • Headache
  • Palpitations
  • Urticaria

Magnesium Sulphate ( MgSO4)

Legal class; class B controlled drugs
Medical class; tocolytic and anticonvulsant
Form; sterile solution for injection
Strength/dosage; 50% of 5 grams/10ml

uterine relaxants magnesium sulphate

Dosage
Loading dose (14g)

4g of MgSO are given slowly intravenously for over 15 to 20 minutes and is prepared as follows

  1. Take a 20ml syringe and draw 8 mils if 50% MgSO4 (4g)
  2. Add 12 mils of water for injection to make 20% of the solution
  3. Give intravenously slowly over 15 minutes.

Immediately this is followed by 10g intramuscular and  is  prepared as follows;

  1. Take 20mils syringe, draw 10mils of 50% MgSO4 (undiluted) which is equivalent to 5g in each syringe
  2. Then add one mil of 2% lignocaine in each syringe to reduce pain
  3. Give deep intramuscular on each buttock
Maintenance Dose

Give 5g of 50% MgSO4 deep intramuscular on alternate buttocks every 4hrs prepare as below.

  1. Take 10ml syringe and draw 10ml of 50% of MgSO4 (5g).
  2. Add 1ml of lignocaine 2% in a syringe and give deep intramuscular.
    The dose can be repeated after every 4hrs of alternate buttock.
  3. The treatment is continued for 24hrs from the time of starting treatment or last fit.
    >  Incase the mother gets fit before 4hours, she is given 2g slowly intravenous.
Useful Effects of MgSO4:
  • Prevent seizures which are associated with pre eclampsia and eclampsia
  • Reduces cerebral oedema
  • Relieves constipation by retaining some water in the lumen
Indications
  •  Severe eclampsia and pre eclampsia
  • Patients with hypomagnesemia
  • Patients with severe asthma
  • Used in short term treatment of constipation
  • Patients with myocardial infarction
Contraindications
  •  Patients with hypermagnesemia
  • Patients who are hypersensitive to MgSO4
  • Renal impairment
  • Hepatic failure
  • Hypotensive patients
  • Patients with epilepsy
Side effects
  •  Drop in blood pressure
  • Flushing of the skin
  •  Dizziness
  •  Confusion
  •  Muscle weakness
  •  Loss of knee jack reflex
  •  Prolonged bleeding time
  •  Excessive bowel activity
Adverse effects
  •  Shock in hypertensive patients
  • Hypermagnesemia
  • Respiratory depression and coma

NIFIDIPINE

Legal class; class B controlled drugs
Medical class; tocolytic and antihypertensive
Form; tablet


Dosage
  •  20mg and the dose is repeated after 30minutes if contractions persists.
  • If contractions continue after 3hrs give 20mg every 3-8hrs until ceased and the maximum dose is 160mg/day

Indications
  •  Threatened abortion
  • Preterm labour less than 34wks of pregnancy
  • Hypertension

Contraindications
  •  Maternal conditions like cardiac diseases
  •  Hypertension
  •  Intrauterine infections
  •  Any condition that make pregnancy to prolong
  •  Fetal death

Side effects
  •  Dizziness
  • Headache
  • Flushing
  • Oedema
  • Fatigue

Uterine Relaxants Read More »

Drugs used in labor

Drugs used in Labor

Drugs used in Labour

Drugs used in labour can be grouped according to the effect they have on the uterus.

  1. Uterine Stimulants/Uterine Mortility drugs. (Oxytocics)
  2. Uterine relaxants (Tocolytics)

Uterine Stimulants/Uterine Motility Drugs(Oxytocics)

Uterine motility drugs stimulate uterine contractions to assist labor (oxytocics) or induce abortion (abortifacients)

Oxytocics

Oxytocics stimulate contraction of the uterus, much like the action of the hypothalamic hormone oxytocin, which is stored in the posterior pituitary. These drugs include

  • Ergonovine (Ergotrate)
  • Methylergonovine (Methergine)
  • Oxytocin (Pitocin, Syntocinon).

Oxytocin

Legal class; class B controlled drugs
Medical class; oxytocic drugs
Form; sterile solution for injection
Strength; 10 IV per ampule.

Indications of Oxytocin
  1.  Induction of labor
  2.  Cases of inter-uterine fetal death.
  3.  Hypotonic uterine contractions
  4.  Mothers with hypertension
  5.  After delivery to control bleeding
  6. Pre-eclampsia and eclampsia
  7.  Congestive cardiac failure
  8.  Post term
  9. Prevent PPH
  10. Incomplete or missed abortion.
  11. Active management of third stage of labor.

Contraindications of Oxytocin
  •  Hypertonic uterine
  •  Fetal and maternal distress
  •  Multiple pregnancy
  •  Trial of labor
  •  Mal presentation like breech, brow
  •  Cephalo pelvic disproportion
  •  Low blood pressure
Dose
  1. Induction/argumentation of labour;  5 I.U into 500mls of solution for infusion, initially, 5 drops per min.
  2. Preventing of PPH after delivery of the placenta; Slow I.V, 5 I.U, increase rate during 3rd stage.

Route
  •  Intramuscular
  • Intravenously when mixed with normal saline or dextrose

Side Effects
  •  Dizziness
  • Nausea and vomiting
  • Rashes
  • Fetal brandy cardia
  • Hypotension

Adverse Effects
  •  Lead to ruptured uterus
  • Hypotension
  • Tachycardia
  • Intra uterine fetal anoxia and hypoxia to the fetus leading to birth asphyxia.
Pharmacokinetics
  •  Absorption is immediate following IV injections
  • Drug is distributed throughout the extracellular fluid. Some amount enters the fetal circulation.
  • It is metabolized rapidly in kidney and liver in small amount and are excreted in urine

Abortifacients

Abortifacients are used to evacuate uterine contents via intense uterine contractions. These drugs include;

  • Misoprostol
  • Carboprost (Hemabate)
  • Dinoprostone (Cervidil, Prepidil Gel, Prostin E2)
  • Mifepristone ( Mifeprex). 

Misoprostol

Legal class; class B controlled drugs
Medical class; oxytocic drugs/ cervical, rippening agent
Form; tablet
Strength; 200mcg/ 100mcg tablet

Indications
  •  Induction of labour
  • Control post partum hemorrhage due to uterine atony
  • Before cervical dilatation
  • Intra-uterine fetal death
  • Gastric and deudenal ulcerations
Contraindications
  •  Mal presentation
  • Placeta previa grade 3 and 4
  • Multiparous mothers
  • Cephalo pelvic disproportion
  • Hypersensitivity to misoprostol
Dose
  • Induction of labour; 100mcg vaginally every after 12hrs
  • NSAID ulcerations; 200mcg 4 times a day
Route
  • Sublingually
  • Rectally
  • Vaginally
Side Effects
  • Headache
  • Dizziness
  • Fever
  • Shivering
  • Vomiting
  • Uterine rupture
  • Fetal distress.
  • Constipation
Pharmacokinetics.

Absorbed in the GIT and distributed widely through out the body metabolised in the liver and is excreted in urine.

DINOPROSTOL

Available preparation – 3mg tab
Available brand – Prostin

Pharmacokinetics

Following vaginal insertion, it diffused slowly into the maternal blood.
There is also some local absorption into the uterus through the cervix
It is distributed widely in the molter, metabolized in the lungs, liver, kidney, spleen and other maternal tissues and excreted in urine with small amount in faeces.

Indications
  • Induction of labor
  • Missed abortion
Contraindications
  •  Active cardiac diseases
  • Multiple pregnancy
  • Hypersentivity to dinoprostol
  • Untreated pelvic infection
  • Caesarian section

Dose :  3 mg vaginally

Side Effects
  •  Abdominal pain
  • Nausea and vomiting
  • Hypotension
  • Shivering
  • Back pain
  • Rapid cervical dilatation

SYNTOMETRINE

Legal class; class B controlled drugs
Medical class; oxytocic drug
Form; sterile solution for injection
Strength; combination of ergometrine and Pitocin ( ergometrine 0.5 mg + Pitocin 5 IU) –It exists in an ampules of 1 mill

Dose
  • I ml as single dose but can be repeated where necessary if bleeding is not controlled
Route
  •    Intramuscular
  •    Intravenous
Indications
  1.  Give to multi gravidas after delivery
  2.   Mothers with a history of post partum hemorrhage
  3. Multiple or twin delivery because of large placental site
  4. Mothers with heavy lochia
  5. Abortion when fundal height is less than 12 weeks
Contraindications

Mothers with cardiac disease, pre eclampsia, eclampsia and hypertension.

Adverse Effects
  •  Retained placenta
  •  IUFD in undiagnosed second twin
  • Lead to retained 2nd twin
  • Uterine rapture if given in abortion, above 20 weeks of gestation products of conception are not fully out.
  • Causes hypoxia and anoxia
Side Effects
  • Nausea and vomiting
  • Headache
  • Hypotension
  • Dyspnea
  • Muscle pain

ERGOMETRINE

Legal class; class B controlled drugs
Medical class; oxytocic drug
Form; tablet and sterile solution
Strength/dosage; tabs 0.25 to 0.5mg tab
Injection 200mcg/ml
0.5mg/ml
EFFECTS
It causes sudden prolonged intermittent uterine contraction
INDICATION
Contra indications
Side effects
Dangers
(Are the same as for syntometrine)

Drugs used in Labor Read More »

Fertility Drugs/ Gonadotropin Drugs drugs

Fertility Drugs/Gonadotropin Drugs

Fertility Drugs

Fertility drugs are drugs that stimulate the female reproductive system.

Examples of Fertility drugs;

  • Cetrorelix (Cetrotide)
  • Chorionic gonadotropin (Chorex, Profasi, Pregnyl).
  • Chorionic gonadotropin alpha (Ovidrel).
  • Clomiphene (Clomid)
  • Menotropins
    (Pergonal, Humegon).

Therapeutic Actions and Indications.

Women without primary ovarian failure who cannot get pregnant after 1 year of trying may be candidates for the use of fertility drugs. Fertility drugs work either directly to stimulate follicles and ovulation or stimulate the hypothalamus to increase FSH and LH levels, leading to ovarian follicular development and maturation of ova.

Indications

  1. Given in sequence with human chorionic gonadotropin (HCG) to maintain the follicle and hormone production, these drugs are used to treat infertility in women with functioning ovaries whose partners are fertile.
  2. Fertility drugs also may be used to stimulate multiple follicle development for the harvesting of ova for in vitro fertilization.
  3. Menotropins also stimulate spermatogenesis in men with low sperm counts and otherwise normally functioning testes.
  4. Cetrorelix inhibits premature LH surges in women undergoing controlled ovarian stimulation by acting as a GnRH antagonist.
  5. Chorionic gonadotropin is used to stimulate ovulation by acting like GnRH and affecting FSH and LH release.

Contraindications of fertility drugs

  1. Allergy to fertility drug:  Prevent hypersensitivity.
  2.  Primary ovarian failure: These drugs only work to stimulate functioning ovaries
  3. Thyroid or adrenal dysfunction. Drugs have effects on the hypothalamic-pituitary axis.
  4. Ovarian cysts: Can be stimulated by the drugs and can become larger
  5. Pregnancy: Due to the potential for serious fetal effects
  6. Idiopathic uterine bleeding: Can represent an underlying problem that could be exacerbated by the stimulatory effects of these drugs.
  7. Lactation: Risk of adverse effects on the baby
  8. Thromboembolic disease. Increased risk of thrombus formation
  9. Women with respiratory diseases: Alterations in fluid volume and blood flow can overtax the respiratory system.

Adverse effects of fertility drugs

  • Greatly increased risk of multiple births and birth defects
  • Ovarian overstimulation: abdominal plain, distention, ascites, pleural effusion
  • Headache
  • Fluid retention
  • Nausea
  • Bloating
  • Uterine bleeding
  • Ovarian enlargement
  • Gynecomastia
  • Febrile reactions possibly due to stimulation of progesterone release.

Fertility Drugs

DrugIndicationDose
Clomifene Anovulatory infertility50mg daily for 5 days, starting within 5 days of onset of menstruation (preferably on the second day) or at any time if cycles have ceased
Bromocriptine Hyper prolactanaemic, infertility, Suppression of lactation, Hypogonadism, Galactorrhoea syndrome, Benign breast diseaseInitially 1.25mg at bed time increased gradually to the usual dose of 2.5mg 3 times a day with food increased if necessary to a max. dose 30mgdaily

Nursing Diagnosis

  • Acute pain related to headache, fluid retention, or GI upset
  • Sexual dysfunction related to alterations in normal hormone control
  • Disturbed body image related to drug treatment and diagnosis
  • Deficient Knowledge regarding drug therapy
  •  Risk for Impaired Tissue Perfusion (Cardiopulmonary, Peripheral) related to increased risk for thrombus formation
  •  Situational Low Self-Esteem related to the need for fertility drugs.

Fertility Drugs/Gonadotropin Drugs Read More »

Estrogen Receptor Modulators

Estrogen Receptor Modulators

Estrogen Receptor Modulators

Estrogen Receptor Modulators are agents that either stimulate or block specific estrogen receptor sites.

They are used to stimulate specific estrogen receptors to achieve therapeutic effects of increased bone mass without stimulating the endometrium and causing other less desirable effects i.e. these drugs stimulate the estrogen receptors in the body so as to produce estrogen as needed by the body.

Examples of Estrogen Receptor Modulators.

Two available estrogen receptor modulators are raloxifene (Evista) and toremifene (Fareston).

Raloxifene

Dose : 60 mg/day Orally.

Indications : Used therapeutically to stimulate specific estrogen receptor sites, which results in an increase in bone mineral density without stimulating the endometrium in women; reduces risk of invasive breast cancer in  postmenopausal women with osteoporosis who are at
high risk for invasive breast cancer

Toremifene

Dose : 60 mg/day orally until disease progression occurs.

Indications: Used as an antineoplastic agent because of its effects on estrogen receptor sites for treatment of advanced breast cancer in postmenopausal women with estrogen receptor–positive and estrogen
receptor–unknown tumors

Contraindications of Estrogen Receptor Modulators
  • Allergy to estrogen receptor modulators.
  • Contraindicated in pregnancy and lactation because of potential effects on the fetus or neonate. 
  •  History of venous thrombosis or smoking. Increased risk of blood clot formation if smoking and estrogen are combined.
Adverse Effects of Estrogen Receptor Modulators
  • Raloxifene has been associated with GI upset, nausea, and vomiting.
  • Changes in fluid balance may cause headache, dizziness, visual changes, and mental changes.
  • Specific estrogen receptor stimulation may cause hot flashes, skin rash, edema, and vaginal bleeding.
Clinically Important Drug–Drug Interactions
  •  Cholestyramine: reduced raloxifene absorption
  • Highly protein-bound drugs (e.g. diazepam, ibuprofen, indomethacin, naproxen): interference on binding sites
  • Warfarin: decreased prothrombin time if taken with raloxifene

Nursing Considerations

  1.  Assess for the mentioned cautions and contraindications (e.g. drug allergies, cardiovascular diseases, metabolic bone disease, history of thromboembolism, etc.) to prevent any complications.
  2. Perform a thorough physical assessment (e.g. bowel sounds, skin assessment, vital signs, mental status, etc.) to establish baseline data before drug therapy begins, to determine effectiveness of
    therapy, and to evaluate for occurrence of any adverse effects associated with drug therapy.
  3. Assist with pelvic and breast examinations. Ensure specimen collection for Pap smear and obtain a history of patient’s menstrual cycle to provide baseline data and to monitor for any adverse
    effects that could occur.
  4. Arrange for ophthalmic examination especially for patients who are wearing contact lenses because hormonal changes can alter the fluid in the eye and curvature of the cornea, which can
    change the fit of contact lenses and alter visual acuity.
  5. Monitor laboratory test results (e.g. urinalysis, renal and hepatic function tests, etc.) to determine possible need for a reduction in dose and evaluate for toxicity.

Nursing Diagnoses
  •  Ineffective tissue perfusion related to changes in the blood vessels brought about by drug therapy and risk of thromboemboli
  • Excess fluid volume related to fluid retention
  • Acute pain related to systemic side effects of gastrointestinal (GI) pain and headache


Implementation with Rationale
These are vital nursing interventions done in patients who are taking female sex hormones and estrogen receptor modulators:

  •  Administer drug with food to prevent GI upset.
  • Provide analgesic for relief of headache as appropriate.
  • Provide small, frequent meals to assist with nausea and vomiting.
  • Monitor for swelling and changes in vision or fit of contact lenses to monitor for fluid retention and fluid changes.
  • Provide comfort measures to help patient tolerate drug effects.
  • Provide safety measures (e.g. adequate lighting, raised side rails, etc.) to prevent injuries.
  • Educate client on drug therapy to promote understanding and compliance.


Evaluation

Here are aspects of care that should be evaluated to determine effectiveness of drug therapy:

  •  Monitor patient response to therapy (palliation of signs and symptoms of menopause, prevention of pregnancy, decreased risk factors for coronary artery disease, and palliation of certain cancers).
  • Monitor for adverse effects (e.g. GI upset, edema, changes in secondary sex characteristics, headaches, thromboembolic episodes, and breakthrough bleeding).
  • Evaluate patient understanding on drug therapy by asking patient to name the drug, its indication, and adverse effects to watch for.
  • Monitor patient compliance to drug therapy

Estrogen Receptor Modulators Read More »

Fertility Drugs/ Gonadotropin Drugs drugs

Gonadotropin drugs

GONADOTROPINS

Gonadotropins are fertility medications given by injection that contain follicle-stimulating hormone (FSH) alone or combined with luteinizing hormone (LH).

Gonadotropins are hormones that stimulate the gonads, which are the sex organs in the body

Gonadotropins are produced by the pituitary gland, which is a small gland located at the base of the brain. The release of gonadotropins is regulated by the hypothalamus.

 

In females, the gonads are the ovaries, and in males, they are the testes.

Gonadotropins are a class of medications used to treat infertility and disorders associated with reproductive functions.

Types of Gonadotropins

There are two main types of gonadotropins:

1. Follicle-stimulating hormone (FSH): This hormone stimulates the growth and development of follicles in the ovaries of females and sperm production in the testes of males.

Females

Males

– Normal Ovarian Function: FSH is useful for the development and maturation of follicles in the ovaries, which contain the eggs. This ensures regular ovulation and fertility.

– Estrogen Production: FSH stimulates the production of estrogen by the growing follicles. Estrogen is for the development of female secondary sexual characteristics, menstrual cycle regulation, and overall reproductive health.

– Improved Egg Quality: FSH contributes to the development of healthy eggs, increasing the chances of successful fertilization and pregnancy.

– Fertility Treatment: FSH is a key component of fertility treatments like in vitro fertilization (IVF) to stimulate multiple egg production.

– Sperm Production: FSH is essential for the production of sperm in the testes. It stimulates the Sertoli cells, which are responsible for nourishing and supporting sperm development.

– Improved Sperm Quality: FSH contributes to the production of healthy, motile sperm, increasing the chances of fertilization.

2. Luteinizing hormone (LH): This hormone triggers ovulation in females and testosterone production in males.

Females

Males

– Ovulation: LH triggers the release of the mature egg from the follicle (ovulation), which is essential for fertilization.

– Corpus Luteum Formation: After ovulation, LH stimulates the formation of the corpus luteum, which produces progesterone. Progesterone is for maintaining the uterine lining for potential pregnancy.

– Hormonal Balance: LH plays a role in regulating the production of estrogen and progesterone, contributing to hormonal balance in the female body.

– Fertility Treatment: LH is used in fertility treatments to trigger ovulation and support the development of the corpus luteum.

– Testosterone Production: LH stimulates the Leydig cells in the testes to produce testosterone. Testosterone is essential for male sexual development, sperm production, and overall health.

– Secondary Sexual Characteristics: LH-driven testosterone production is responsible for the development of male secondary sexual characteristics like facial hair, muscle mass, and deepening of the voice.

– Libido and Sexual Function: Testosterone, produced under the influence of LH, plays a crucial role in libido and sexual function.

GONADOTROPIN DRUGS (Fertility Drugs)

Gonadotropin Drugs/Fertility drugs are agents that stimulate the female reproductive system.

Fertility drugs are medications used to help women who are having trouble getting pregnant. They work by stimulating the ovaries to produce more eggs, increasing the chances of conception.

Indications for Fertility Drugs:

1. Treatment of infertility in women with functioning ovaries whose partners are fertile: This is a broad category encompassing various causes of infertility, including:

  • Anovulation: When a woman doesn’t ovulate regularly, fertility drugs can stimulate ovulation and increase the chances of pregnancy.
  • Polycystic Ovarian Syndrome (PCOS): PCOS often causes irregular ovulation. Fertility drugs can help regulate ovulation and improve fertility.
  • Endometriosis: This condition can affect ovulation and egg quality. Fertility drugs can help stimulate ovulation and improve chances of conception.
  • Premature Ovarian Failure: In some cases, women experience premature ovarian failure, leading to low egg reserves. Fertility drugs can help stimulate limited egg production.
  • Unexplained Infertility: When the cause of infertility is unknown, fertility drugs can be used to stimulate ovulation and see if it improves chances of pregnancy.

2. Used to stimulate multiple follicle development for harvesting of ova for in vitro fertilization (IVF): This is a crucial aspect of IVF, where multiple eggs are needed for fertilization and embryo transfer.

3. Menotropins are used to stimulate spermatogenesis in men with low sperm counts and otherwise normally functioning testes: While not directly related to female fertility, this highlights the broader application of fertility drugs in both men and women.

Contraindications for Fertility Drugs:
  1. Allergy to fertility drug: Prevent hypersensitivity reactions.
  2. Primary ovarian failure: These drugs only work to stimulate functioning ovaries.
  3. Ovarian cysts: Can be stimulated by the drugs and can become larger.
  4. Pregnancy: Due to the potential for serious fetal effects.
  5. Idiopathic uterine bleeding: Can represent an underlying problem that could be exacerbated by the stimulatory effects of these drugs.
  6. Lactation: Risk of adverse effects on the baby.
  7. Thromboembolic disease: Increased risk of thrombus formation.
  8. Women with respiratory diseases: Alterations in fluid volume and blood flow can overtax the respiratory system.
Adverse Effects:
  • Greatly increased risk of multiple births and birth defects.
  • Ovarian overstimulation: abdominal pain, distention, ascites, pleural effusion.
  • Others: headache, fluid retention, nausea, bloating, uterine bleeding, ovarian enlargement, gynecomastia, and febrile reactions possibly due to stimulation of progesterone release.
  • Fluid retention is a common side effect of fertility medications, because;

    Hormonal Changes: Fertility drugs increase estrogen levels, which can lead to fluid retention. Estrogen promotes sodium retention in the body, and sodium attracts water, causing fluid buildup.

    Increased Blood Flow: Fertility drugs increase blood flow to the ovaries and uterus, which can lead to fluid buildup in the pelvic area.

Drugs used in treatment of infertility

Name

Clinical uses and dosage

Contraindications

Clomifene


  • Available in tablet form of 50mg

  • Brand name Clomid

Infertility due to failure to ovulate.

Given 50 mg daily × 5/7

Starting from the 5th day of the cycle ,

Increase to 100mg ×5/7

From day 5-10 if no response.

Pregnancy.

Bromocriptine


  • Available in tablet form of 2.5mg

Female infertility associated with hyperprolactinemia

Dosage 1.25 – 2.5mg

Bid × 3-7 days with food.

Inhibition of lactation 2.5mg bid with meals × 14 days.

 

Severe ischemic heart disease

Uncontrolled hypertension

Pregnancy

Breast feeding.

FEMALE REPRODUCTIVE SYSTEM DRUGS

Drugs that affect the female reproductive system typically include hormones and hormonal-like agents.

These drug types include;

  1.  Female Sex Hormones
  2. Estrogen Receptor Modulators
  3. Fertility Drugs/gonadotropins
  4. Drugs used in labor
  5. Abortifacients
gonadotropin sites

Gonadotropin Sites of Action

Female Sex Hormones

The female sex hormones can be used to replace hormones that are missing or to act on the control mechanisms of the endocrine system to decrease the release of endogenous hormones.
Drugs that act like estrogen, particularly at specific estrogen receptors, are also used to stimulate the effects of estrogen in the body with fewer of the adverse effects.

Female sex hormones include;

  • Estrogens 
  • Progestins

Estrogens.

This hormone is naturally produced by the ovaries, placenta and adrenal glands. It stimulates the development of female sex characteristics, prepares the body for pregnancy, affects the release of FSH and LH, and is responsible for proliferation of the endometrial lining.

Low estrogen in the body is responsible for the signs and symptoms of menopause, in the uterus, vagina, breast and cervix.

Other Functions of estrogen include;

  1. Breast development.
  2. Increase cholesterol in bile, to prevent damaging effects of bile salts.
  3. Increases fat storage, such as in breast tissue.
  4. Maintains bone mineral density.
  5. Maintains muscle strength.
  6. Prevents atherosclerosis, by increasing HDL concentration and lowering LDL.
  7. Estrogen is responsible for maintaining libido, memory, and mental health. 
  8. It stimulates ovulation, maintains the uterine walls and is important in vaginal lubrication.
Indications of Estrogen Therapy.
  • Estrogens are used for hormone replacement therapy (HRT) when ovarian activity is blocked or absent.
  • Is used to control the signs and symptoms of menopause.
  • They can also be used in therapy for prostate cancer and inoperable breast cancer, also as palliative care.
  • Treatment of female hypogonadism(when the body produces little or no hormones).
  • Treat ovarian failure.
  • Oral contraceptives (estrogen and progestin)
  • Morning after pill (emergency pills)
  • Endometriosis
  • Dysmenorrhea, used with progestin.

Progestin/Progesterone.

This promotes maintenance of pregnancy and it is called a pregnancy hormone.

Its functions include;

  1. Transforms proliferative endometrium into secretory endometrium.
  2. Prevents follicle maturation, ovulation and uterine contractions.
  3. Used in contraceptives. It inhibits release of GnRH, FSH and LH, hence follicle development and ovulation are prevented.
Indications of Progestin.
  • Used as a contraceptive.
  • Maintains pregnancy and development of secondary sex characteristics.
  • Use to treat primary and secondary amenorrhea, and functional uterine bleeding.
  • Treatment of acne and premenstrual dysphoric disorder (PMDD).
  • For the relief of signs and symptoms of menopause .
Contraindications of Female Sex hormones.

Estrogen

  • Known allergies
  • Idiopathic vaginal bleeding.
  • Breast Cancer(Estrogen dependant cancer)
  • CVA since it increases clotting factor prodn.
  • Hepatic dysfunction.
  • Pregnancy.
  • Lactation.

Progestin/Progesterone

  • PID
  • STD
  • Endometriosis
  • Renal and hepatic disorders.
  • Epilepsy.
  • Asthma.
  • Migraine headaches
  • Cardiac Dysfunction —potential excerbation.
Adverse Effects.
  • Corneal Changes.
  • Photosensitivity.
  • Peripheral edema.
  • Chloasma ( patches on the face)
  • Hepatic adenoma.
  • Nausea
  • Vomiting.
  • Abdominal cramps.
  • Bloating.
  • Withdraw bleeding.
  • Changes in menstrual flow.

Important aspects/issues to remember.

  1.  Women receiving any of these drugs should receive an annual medical examination, including
    breast examination and Pap smear, to monitor for adverse effects and underlying medical
    conditions.
  2. Women taking estrogen should be advised not to smoke because of the increased risk of
    thrombotic events.
  3. Women who are receiving these drugs for fertility programs should receive a great deal of psychological support and comfort measures to cope with the many adverse effects associated
    with these drugs. The risk of multiple births should be explained.
  4. Drugs are used in treatment of specific cancers in males and they should be advised about the
    possibility of estrogenic effects.
  5. Not indicated during pregnancy or lactation because of potential for adverse effects on the fetus
    or neonate.
Examples of female sex hormones and dosages.

Estrogen

  1. Estradiol, 1–2 mg/day orally or  1–5 mg IM every 3–4 weeks or  2–4 g intravaginal cream daily.
  2. Estrogens, conjugated (C.E.S., Premarin), 0.3–1.25 mg/day orally.
  3. Estropipate (Ortho-Est, Ogen), 0.625–5 mg/day orally.

Progestin/Progesterone.

  1. Etonogestrel (Implanon) 68 mg implanted sub dermally for up to 3 yr, replaced or changed when needed.
  2. Medroxyprogesterone (Provera) 5–10 mg/day PO for 5–10 days for amenorrhea or 400–1000 mg/week IM for cancer therapy or 150 mg of deep IM every 3 months (13 weeks) for contraception.
Clinically important Drug Interactions

Estrogen

  •  Barbiturates, rifampin, tetracyclines, phenytoin: decreased serum estrogen levels
  • Corticosteroids: increased therapeutic and toxic effects of corticosteroids.
  • Nicotine: Increased risk of thrombi and emboli
  • Grapefruit juice: inhibition of metabolism of estradiols
  • St. John’s wort: can affect metabolism of estrogens and can make estrogen-containing
    contraceptives less effective.

Progestins

  •  Barbiturates, carbamazepine, phenytoin, griseofulvin, penicillin, tetracyclines, rifampin: reduced
    effectiveness of progestins
  • St. John’s wort: can affect the metabolism of progestins and can make progestin-containing
    contraceptives less effective..

Gonadotropin drugs Read More »

pneumonia in children

Pneumonia in Children

Pediatric Pneumonia Lecture Notes
Pediatric Pneumonia

Pneumonia remains a leading cause of morbidity and mortality in children worldwide, especially in developing countries. Its epidemiology and etiology differ significantly from adults, largely due to variations in immune system maturity, exposure patterns, and anatomical differences.

Pneumonia is an acute inflammatory condition of the lung parenchyma caused by an infection.

  • lung parenchyma is the the functional tissue of the lungs, specifically the alveoli and bronchioles.

This inflammation leads to the filling of the alveolar spaces with exudate, cells, and fluid, a process known as consolidation. This consolidation impairs gas exchange, leading to symptoms such as cough, fever, chills, and difficulty breathing.

In simpler terms, pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus (purulent material), causing cough with phlegm or pus, fever, chills, and trouble breathing.

Classifications of Pneumonia

Pneumonia can be classified in various ways, each providing a different lens through which to understand its cause, presentation, and management.

A. By Etiology (Cause of Infection):

This classification focuses on the specific microorganism responsible for the infection.

  1. Bacterial Pneumonia: The most common type, often more severe than viral pneumonia.
    • Common Pathogens:
      • Streptococcus pneumoniae (Pneumococcus): The most frequent cause of community-acquired bacterial pneumonia.
      • Haemophilus influenzae.
      • Staphylococcus aureus (including MRSA).
      • Klebsiella pneumoniae.
      • Mycoplasma pneumoniae (often called "walking pneumonia" due to milder symptoms).
      • Chlamydophila pneumoniae.
      • Legionella pneumophila (Legionnaires' disease).
  2. Viral Pneumonia: Often milder than bacterial pneumonia but can be severe, especially in infants, elderly, and immunocompromised individuals.
    • Common Pathogens:
      • Influenza viruses (Types A and B).
      • Respiratory Syncytial Virus (RSV).
      • Adenoviruses.
      • Parainfluenza viruses.
      • Human Metapneumovirus.
      • Coronaviruses (e.g., SARS-CoV, MERS-CoV, SARS-CoV-2).
  3. Fungal Pneumonia: Less common, usually affecting individuals with weakened immune systems or those exposed to large amounts of fungi in the environment.
    • Common Pathogens:
      • Pneumocystis jirovecii (PCP pneumonia, common in HIV/AIDS patients).
      • Histoplasma capsulatum (Histoplasmosis).
      • Coccidioides immitis (Coccidioidomycosis or Valley Fever).
      • Blastomyces dermatitidis (Blastomycosis).
      • Aspergillus species.
  4. Parasitic Pneumonia: Rare, caused by parasites, usually seen in immunocompromised individuals or those who have traveled to endemic areas.
    • Common Pathogens:
      • Toxoplasma gondii.
      • Strongyloides stercoralis.
  5. Aspiration Pneumonia: Occurs when foreign material (e.g., food, liquid, vomit, stomach contents) is inhaled into the lungs, leading to inflammation and often secondary bacterial infection.
    • Causes: Impaired swallowing mechanisms, altered consciousness, gastroesophageal reflux.
  6. Chemical Pneumonia (Pneumonitis): Lung inflammation caused by inhaling irritating chemicals or toxic gases, rather than an infectious agent. This is not an infection but can predispose to one.
    • Causes: Inhalation of smoke, noxious fumes, or gastric acid.
B. By Anatomical Location (Area of Lung Affected):

This classification describes the pattern of lung involvement as seen on chest imaging.

  1. Lobar Pneumonia: Affects a large, continuous area of an entire lobe of a lung. Often caused by Streptococcus pneumoniae.
    • Appearance: Typically seen as a dense, homogeneous consolidation on chest X-ray.
  2. Bronchopneumonia (or Lobular Pneumonia): Characterized by patchy consolidation centered around the bronchi and bronchioles, often affecting multiple lobes. More common in infants, young children, and the elderly.
    • Appearance: Patchy infiltrates on chest X-ray, often bilateral and basal.
  3. Interstitial Pneumonia: Involves the interstitial spaces of the lung (the tissue between the alveoli and capillaries), rather than primarily the air sacs. More commonly associated with viral or atypical bacterial infections.
    • Appearance: Reticular or reticulonodular patterns on chest X-ray.
  4. Miliary Pneumonia: A form of pneumonia characterized by the wide dissemination of an infectious agent (Mycobacterium tuberculosis) throughout the lung tissue in small, discrete lesions resembling millet seeds.
    • Appearance: Fine, diffuse nodular infiltrates throughout both lungs on chest X-ray.
C. By Duration:

This classification refers to the time course of the illness.

  1. Acute Pneumonia: Rapid onset and progression of symptoms, typically resolving within days to a few weeks with appropriate treatment. Most common form.
  2. Chronic Pneumonia: Persistent symptoms and radiological findings lasting for weeks to months, or even longer. Often associated with specific pathogens (e.g., Mycobacterium tuberculosis, fungi) or underlying conditions.
D. By Clinical Grounds / Acquisition Setting:

This is one of the most clinically relevant classifications, as it guides initial empiric treatment decisions.

  1. Community-Acquired Pneumonia (CAP): Pneumonia acquired outside of hospitals or long-term care facilities.
    • Common Pathogens: Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Haemophilus influenzae, influenza virus.
  2. Hospital-Acquired Pneumonia (HAP) / Nosocomial Pneumonia: Pneumonia that develops 48 hours or more after hospital admission and was not incubating at the time of admission.
    • Common Pathogens: Often more virulent and antibiotic-resistant bacteria, such as Pseudomonas aeruginosa, Staphylococcus aureus (MRSA), Klebsiella species, Escherichia coli.
  3. Ventilator-Associated Pneumonia (VAP): A subtype of HAP that develops in patients who have been mechanically ventilated for more than 48 hours.
    • Common Pathogens: Similar to HAP, often highly resistant organisms.
Etiology of Pneumonia

The etiology refers to the specific agents or organisms responsible for causing pneumonia. As discussed in Objective 1, these can be broadly categorized.

A. Common Bacterial Pathogens:

These are the most frequent causes of pneumonia, especially bacterial pneumonia.

  1. Streptococcus pneumoniae (Pneumococcus):
    • Description: The leading cause of community-acquired bacterial pneumonia (CAP) in all age groups, particularly in adults.
    • Characteristics: Gram-positive coccus, typically arranged in pairs (diplococci). Has a polysaccharide capsule that protects it from phagocytosis.
    • Risk Factors: Old age, chronic lung disease, recent viral infection, immunocompromised status.
  2. Haemophilus influenzae:
    • Description: A common cause of both CAP and HAP, especially in individuals with chronic obstructive pulmonary disease (COPD) or other underlying lung conditions.
    • Characteristics: Gram-negative coccobacillus.
    • Risk Factors: COPD, cystic fibrosis, alcoholism.
  3. Staphylococcus aureus:
    • Description: Can cause severe pneumonia, often seen as HAP or as a complication of viral infections (e.g., influenza). Methicillin-resistant S. aureus (MRSA) is a significant concern, especially in VAP and HCAP.
    • Characteristics: Gram-positive coccus, often arranged in clusters. Produces various toxins.
    • Risk Factors: Recent influenza, injection drug use, skin/soft tissue infection, hospitalization, surgical procedures.
  4. Klebsiella pneumoniae:
    • Description: A common cause of HAP and, less frequently, severe CAP, particularly in individuals with alcoholism or diabetes. Known for causing "currant jelly" sputum.
    • Characteristics: Gram-negative rod, often encapsulated.
    • Risk Factors: Alcoholism, diabetes, chronic lung disease, hospitalization.
  5. Pseudomonas aeruginosa:
    • Description: A significant cause of HAP and VAP, particularly in immunocompromised patients, those with cystic fibrosis, or prolonged hospital stays. Difficult to treat due to antibiotic resistance.
    • Characteristics: Gram-negative rod.
    • Risk Factors: Cystic fibrosis, bronchiectasis, mechanical ventilation, broad-spectrum antibiotic use, immunocompromised state.
  6. Mycoplasma pneumoniae:
    • Description: A common cause of "atypical pneumonia" or "walking pneumonia" in young adults and school-aged children. Causes milder, but prolonged, symptoms.
    • Characteristics: Lacks a cell wall, making it resistant to many common antibiotics (e.g., penicillin).
  7. Chlamydophila pneumoniae:
    • Description: Another cause of atypical pneumonia, often with milder symptoms.
    • Characteristics: Obligate intracellular bacterium.
  8. Legionella pneumophila:
    • Description: Causes Legionnaires' disease, a severe form of pneumonia often associated with contaminated water sources (e.g., air conditioning systems, hot tubs).
    • Characteristics: Gram-negative rod, fastidious growth requirements.
B. Common Viral Pathogens:

Viruses are a very common cause of pneumonia, especially in children. They can also predispose to secondary bacterial infections.

  1. Influenza Viruses (A and B): Seasonal epidemics cause widespread respiratory illness, including primary viral pneumonia and often secondary bacterial pneumonia.
  2. Respiratory Syncytial Virus (RSV): The most common cause of lower respiratory tract infections in infants and young children, often leading to bronchiolitis and pneumonia.
  3. Adenoviruses: Can cause a range of respiratory illnesses, including pneumonia, particularly in children and immunocompromised individuals.
  4. Parainfluenza Viruses: Common cause of croup, but can also cause bronchiolitis and pneumonia, especially in children.
  5. Coronaviruses (e.g., SARS-CoV-2): Various coronaviruses can cause respiratory infections, with SARS-CoV-2 (COVID-19) being a notable cause of severe viral pneumonia and acute respiratory distress syndrome (ARDS).
C. Common Fungal Pathogens:

More prevalent in immunocompromised individuals or specific geographic regions.

  1. Pneumocystis jirovecii: Causes Pneumocystis pneumonia (PCP), a common and severe opportunistic infection in individuals with HIV/AIDS.
  2. Endemic Fungi (e.g., Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis): Found in specific geographic areas. Exposure to spores can lead to pneumonia, especially in immunocompromised individuals.
  3. Aspergillus species: Can cause invasive aspergillosis, a severe pneumonia, primarily in severely immunocompromised patients (e.g., transplant recipients, leukemia patients).
D. Aspiration of Gastric Contents/Foreign Material:

Not an infectious agent itself, but the aspiration of acidic gastric contents or other foreign material can cause a severe chemical pneumonitis, which then often becomes secondarily infected by oral flora (anaerobic bacteria).

Pathogenesis of Pneumonia

Pathogenesis describes the sequence of events that leads to the development of pneumonia, from initial exposure to clinical symptoms.

A. Normal Host Defenses:

The respiratory tract has several protective mechanisms to prevent infection:

  1. Upper Airway Filtration: Nasal hairs, turbinates, and mucous membranes filter out large particles.
  2. Epiglottis and Cough Reflex: Protect the lower airways from aspiration.
  3. Mucociliary Escalator: Ciliated epithelial cells line the trachea and bronchi, moving mucus (which traps pathogens) upwards for expectoration or swallowing.
  4. Alveolar Macrophages: Phagocytic cells in the alveoli that engulf and destroy pathogens and debris.
  5. Humoral and Cellular Immunity: Antibodies (IgA, IgG) and T lymphocytes provide specific immunity.
Mechanisms of Pathogen Entry:

Pneumonia develops when pathogens overcome or bypass these host defenses.

  1. Aspiration (Most Common): Microaspiration of oropharyngeal secretions containing pathogens is the most frequent route. This happens constantly in small amounts, but typically the host defenses clear them. Impaired consciousness, dysphagia, or presence of a nasogastric tube increases the risk of significant aspiration.
  2. Inhalation: Airborne pathogens (e.g., viruses, Mycoplasma, Legionella, fungi) can be inhaled directly into the lower respiratory tract.
  3. Hematogenous Spread: Pathogens from a distant site of infection (e.g., endocarditis, IV drug use, abdominal sepsis) can travel through the bloodstream to the lungs.
  4. Direct Spread: Less common, but can occur from contiguous infected sites (e.g., empyema spreading to lung, trauma).
Pathophysiology:

Once pathogens reach the lower respiratory tract and evade local defenses, a series of events leads to inflammation and consolidation:

  1. Colonization and Multiplication: Pathogens colonize the alveoli and/or terminal bronchioles and begin to multiply.
  2. Immune Response and Inflammation:
    • Alveolar Macrophages: Are typically the first line of defense. If overwhelmed, they release cytokines (e.g., TNF-alpha, IL-1, IL-6, IL-8).
    • Neutrophil Recruitment: These cytokines attract neutrophils from the bloodstream into the alveolar spaces.
    • Increased Vascular Permeability: The inflammatory response causes vasodilation and increased permeability of the alveolar-capillary membrane.
  3. Fluid Exudation and Consolidation:
    • Plasma fluid, red blood cells, and fibrin leak into the alveolar spaces.
    • Neutrophils and bacteria fill the alveoli.
    • This mixture of fluid, cells, and debris leads to the characteristic consolidation seen in pneumonia, where the lung tissue becomes dense and airless.
  4. Impaired Gas Exchange:
    • The consolidated alveoli can no longer participate in gas exchange.
    • This leads to ventilation-perfusion mismatch (areas are perfused but not ventilated), resulting in hypoxemia (low blood oxygen).
    • The increased work of breathing due to decreased lung compliance and airway obstruction can also lead to hypercapnia (high blood carbon dioxide) in severe cases.
  5. Tissue Damage: The inflammatory process and release of bacterial toxins can cause damage to the alveolar and bronchial epithelial cells, impairing mucociliary function and further propagating inflammation.
  6. Resolution: With effective immune response and/or antibiotic treatment, the inflammation subsides, macrophages clear cellular debris, and the exudate is reabsorbed, allowing the lung to return to normal function.
Etiology of Pediatric Pneumonia (Causative Agents)

The pathogens responsible for pneumonia vary significantly by age group.

A. Neonates (Birth to 1 Month):
  • Pneumonia in neonates is often acquired perinatally (from the mother during birth) or nosocomially (in the hospital).
  • Bacterial:
    • Group B Streptococcus (GBS): Common cause of early-onset neonatal sepsis and pneumonia.
    • Gram-negative enteric bacilli: Escherichia coli, Klebsiella pneumoniae.
    • Listeria monocytogenes.
  • Viral: Less common primary cause, but can be involved (e.g., Herpes Simplex Virus - HSV).
  • B. Infants (1 Month to 6 Months):
  • Transition period, with a mix of perinatal pathogens and increasing community-acquired pathogens.
  • Bacterial:
    • Streptococcus pneumoniae (pneumococcus): Increasingly common.
    • Haemophilus influenzae (non-typeable or type b if unvaccinated).
    • Staphylococcus aureus: Can cause severe disease.
  • Atypical Bacteria:
    • Chlamydia trachomatis: Can cause afebrile pneumonia, often associated with conjunctivitis, transmitted from mother during birth. Presents at 2-12 weeks of age.
    • Bordetella pertussis (whooping cough): Can cause severe pneumonia, especially in unvaccinated infants.
  • Viral (Most Common Overall):
    • Respiratory Syncytial Virus (RSV): The leading cause of bronchiolitis and pneumonia in infants.
    • Parainfluenza viruses: (Types 1, 2, 3).
    • Adenovirus: Can cause severe and prolonged disease.
    • Influenza viruses: (A and B).
    • Human Metapneumovirus.
  • C. Preschool Children (6 Months to 5 Years):
  • Viral (Still Most Common):
    • RSV, Influenza, Parainfluenza, Adenovirus, Human Metapneumovirus, Rhinovirus.
  • Bacterial:
    • Streptococcus pneumoniae (Pneumococcus): Remains the most frequent bacterial cause.
    • Haemophilus influenzae (non-typeable).
    • Staphylococcus aureus (including MRSA).
    • Streptococcus pyogenes (Group A Strep): Less common but can cause severe pneumonia.
  • Atypical Bacteria:
    • Mycoplasma pneumoniae: Becomes more common in this age group, though classically associated with school-aged children.
  • D. School-Aged Children and Adolescents (> 5 Years):
  • The spectrum of pathogens begins to resemble that of adults.
  • Atypical Bacteria (Increasingly Common):
    • Mycoplasma pneumoniae: The most common cause of "atypical pneumonia" or "walking pneumonia."
    • Chlamydophila pneumoniae.
  • Bacterial:
    • Streptococcus pneumoniae.
    • Staphylococcus aureus (including MRSA).
    • Haemophilus influenzae.
    • Streptococcus pyogenes.
  • Viral:
    • Influenza A and B.
    • Adenovirus.
  • E. Less Common but Important Causes (Across Age Groups):
  • Tuberculosis (Mycobacterium tuberculosis): Consider in endemic areas or with risk factors.
  • Fungal Pneumonia: (e.g., Pneumocystis jirovecii pneumonia - PCP) primarily in immunocompromised children.
  • Aspiration Pneumonia: In children with feeding difficulties, GERD, or neurological impairment.
  • Clinical Presentation of Pneumonia in Children

    Recognize age-specific manifestations and indicators of severity to ensure timely intervention.

    I. General Signs and Symptoms of Pneumonia in Children
  • Cough: May be dry, moist, or productive (though young children rarely expectorate sputum). Can sometimes be the only prominent symptom.
  • Tachypnea (Increased Respiratory Rate): Often the most sensitive and specific sign of pneumonia in children, especially in infants. Defined as:
    • < 2 months: ≥ 60 breaths/min
    • 2-11 months: ≥ 50 breaths/min
    • 1-5 years: ≥ 40 breaths/min
    • 5 years: ≥ 20 breaths/min
  • Fever: Present in many cases, but can be absent, especially in neonates, young infants, or immunocompromised children.
  • Dyspnea (Difficulty Breathing): Manifested as increased work of breathing.
  • Lethargy / Irritability: Non-specific signs of illness in children.
  • Poor Feeding / Decreased Oral Intake: Common in infants and young children.
  • Chest Pain: More common in older children, often pleuritic (sharp, worse with breathing).
  • Abdominal Pain: Can be referred pain from diaphragmatic irritation, especially in lower lobe pneumonia.
  • II. Age-Specific Clinical Manifestations
    A. Neonates (Birth to 1 Month):
  • Pneumonia in neonates is often subtle and non-specific, making diagnosis challenging.
  • Non-specific Signs:
    • Respiratory Distress: Tachypnea (often the earliest sign), grunting, nasal flaring, retractions (subcostal, intercostal, suprasternal).
    • Apnea: Pauses in breathing, especially in premature infants.
    • Cyanosis (bluish discoloration) or pallor.
    • Lethargy, irritability, hypotonia.
    • Poor feeding, vomiting.
    • Temperature instability (hypothermia is common, fever less so).
    • Jaundice.
  • Physical Exam: May reveal decreased breath sounds, crackles (rales), or wheezing.
  • B. Infants (1 Month to 1 Year):
  • More overt signs of respiratory illness are typically present.
  • Key Signs:
    • Tachypnea: Always a critical sign.
    • Retractions: Subcostal, intercostal, suprasternal, supraclavicular.
    • Nasal Flaring.
    • Grunting: Short, low-pitched sounds during expiration, attempting to increase end-expiratory pressure.
    • Cough: Can be prominent, may be paroxysmal, especially with Pertussis or viral causes like RSV.
    • Fever.
    • Poor feeding, decreased activity.
    • Wheezing (more common with viral pneumonia/bronchiolitis).
  • Physical Exam: Crackles, decreased breath sounds, dullness to percussion (if consolidation is significant).
  • C. Toddlers and Preschoolers (1 Year to 5 Years):
  • Similar to infants, but with more verbal communication of symptoms.
  • Key Signs:
    • Tachypnea.
    • Cough: Often harsh and persistent.
    • Fever.
    • Dyspnea, increased work of breathing.
    • Lethargy, irritability, decreased playfulness.
    • Decreased appetite.
    • Abdominal pain: Can be a presenting complaint, particularly with lower lobe pneumonia irritating the diaphragm.
  • Physical Exam: Crackles, rhonchi, decreased breath sounds, dullness to percussion.
  • D. School-Aged Children and Adolescents (> 5 Years):
  • Clinical presentation begins to resemble adult pneumonia.
  • Key Signs:
    • Cough: Can be productive with sputum, especially in bacterial pneumonia.
    • Fever and Chills.
    • Dyspnea / Shortness of Breath.
    • Pleuritic Chest Pain: Sharp pain worsened by breathing or coughing.
    • Headache, malaise, myalgia.
    • Abdominal pain.
    • "Atypical" Pneumonia (e.g., Mycoplasma pneumoniae): Often presents with more insidious onset, low-grade fever, persistent dry cough, headache, and malaise, sometimes called "walking pneumonia."
  • Physical Exam: Crackles, egophony, decreased breath sounds, dullness to percussion.
  • III. Indicators of Severe Pneumonia / Respiratory Distress in Children

    Rapid recognition of these signs is critical for determining the need for hospitalization and intensive care.

  • Inability to Feed/Drink: Especially in infants and young children.
  • Severe Respiratory Distress:
    • Severe Tachypnea (respiratory rate significantly above age-appropriate limits).
    • Severe Retractions (all types, especially supraclavicular, tracheal tug).
    • Grunting.
    • Nasal Flaring.
    • Central Cyanosis: Bluish discoloration of the tongue, lips, and nail beds, indicating hypoxemia.
    • Head Bobbing: Especially in infants.
  • Altered Mental Status: Lethargy, extreme irritability, difficult to arouse, confusion.
  • Hypoxemia: SpO2 < 90% (or lower, depending on altitude and clinical context) on room air.
  • Signs of Dehydration.
  • Signs of Shock: Tachycardia, poor perfusion, hypotension (a late sign in children).
  • Diagnostic Approaches for Pneumonia in Children
    Clinical Assessment (The Most Important Step):
  • History:
    • Onset and duration of symptoms (fever, cough, respiratory distress, feeding difficulties).
    • Exposure history (sick contacts, daycare, travel).
    • Vaccination status.
    • Risk factors (prematurity, underlying medical conditions).
    • Medication history.
  • Physical Examination:
    • General Appearance: Alertness, activity level, signs of distress.
    • Vital Signs: Respiratory rate (most sensitive sign of pneumonia), heart rate, temperature, blood pressure.
    • Respiratory Examination:
      • Inspection: Work of breathing (retractions, nasal flaring, grunting), cyanosis, symmetry of chest movement.
      • Palpation: Tactile fremitus (may be increased over consolidation, but difficult in young children).
      • Percussion: Dullness over consolidated areas or pleural effusion.
      • Auscultation:
        • Crackles (rales): Suggestive of alveolar inflammation/fluid.
        • Bronchial breath sounds: Over consolidated lung tissue.
        • Wheezing: More common in viral causes or with underlying reactive airway disease.
        • Decreased or absent breath sounds: May indicate consolidation or pleural effusion.
    • Other Systems: Assess for dehydration, cardiac involvement, neurological status.
  • Pulse Oximetry:
    • Essential non-invasive test in all children suspected of having pneumonia.
    • Measures oxygen saturation (SpO2). Hypoxemia (SpO2 < 90-92% on room air) is a strong indicator of severity and often guides hospitalization and oxygen therapy.
    Chest Radiography (CXR):
  • Indications:
    • Typically not recommended for routine diagnosis of uncomplicated community-acquired pneumonia in children who can be managed as outpatients and whose diagnosis is clear clinically.
    • Recommended for:
      • Children with severe pneumonia.
      • Uncertain diagnosis, or if differential diagnoses like foreign body aspiration are considered.
      • Failure to respond to initial empiric therapy.
      • Suspicion of complications (e.g., pleural effusion, empyema, abscess).
      • Recurrent pneumonia.
  • Findings:
    • Lobar Consolidation: Suggests bacterial pneumonia.
    • Interstitial Infiltrates: More characteristic of viral or atypical pneumonia.
    • Bronchial Wall Thickening/Peribronchial Cuffing: Common in viral infections.
    • Pleural Effusion, Empyema, Pneumothorax: Indicate complications.
    • Hyperinflation: Common in viral bronchiolitis.
  • Limitations:
    • Cannot reliably distinguish between bacterial and viral pneumonia.
    • Poor correlation between radiological findings and clinical severity.
    • Radiation exposure.
  • Laboratory Tests:
  • Blood Cultures:
    • Generally NOT recommended for routine CAP in outpatient settings.
    • Consider for: Hospitalized children with severe pneumonia, immunocompromised children, suspicion of bacteremia. Low yield (typically < 1-2%).
  • Complete Blood Count (CBC) with Differential:
    • Not routinely recommended for uncomplicated CAP.
    • May show leukocytosis with neutrophilia in bacterial infection, or lymphocytosis in viral infection, but findings can overlap and are not definitive.
  • Inflammatory Markers (e.g., C-reactive protein (CRP), Procalcitonin):
    • May be elevated in bacterial infections, but also in severe viral infections.
    • Not routinely used for initial diagnosis but can sometimes aid in differentiating bacterial from viral, or monitoring response to treatment.
  • Viral Diagnostics (e.g., Nasopharyngeal Swabs for PCR):
    • Recommended for: All hospitalized infants and young children with suspected viral pneumonia/bronchiolitis (e.g., RSV, influenza, adenovirus, parainfluenza).
    • Important for infection control, cohorting patients, and avoiding unnecessary antibiotic use.
    • Does not rule out bacterial co-infection.
  • Sputum Culture:
    • Difficult to obtain in young children, often contaminated by upper airway flora. Not routinely recommended.
  • Pleural Fluid Analysis:
    • If pleural effusion is present, diagnostic thoracentesis may be performed to identify the pathogen and guide treatment for empyema.
  • Tuberculin Skin Test (TST) / Interferon-Gamma Release Assay (IGRA):
    • Consider in children with persistent or recurrent pneumonia, or risk factors for tuberculosis.
  • Serology for Atypical Pathogens (e.g., Mycoplasma pneumoniae, Chlamydia pneumoniae):
    • Can be useful for retrospective diagnosis, but acute and convalescent titers are needed, so not helpful for acute management.
  • Differential Diagnoses

    Many conditions can mimic pneumonia in children due to similar respiratory symptoms.

    1. Upper Respiratory Tract Infection (URI) / Common Cold: Often presents with cough, rhinorrhea, low-grade fever. Absence of tachypnea and significant work of breathing usually differentiates it from pneumonia.
    2. Bronchiolitis: Common in infants < 2 years, primarily caused by RSV. Presents with cough, rhinorrhea, tachypnea, prominent wheezing, and crackles. Often difficult to distinguish clinically from viral pneumonia, and they can coexist.
    3. Asthma Exacerbation / Reactive Airway Disease: Wheezing, cough, dyspnea. History of recurrent episodes or triggers may point to asthma.
    4. Foreign Body Aspiration: Sudden onset of choking, coughing, dyspnea, particularly in toddlers. Can lead to unilateral wheezing or recurrent localized pneumonia. A high index of suspicion is needed. CXR may show unilateral hyperinflation or atelectasis.
    5. Croup (Laryngotracheobronchitis): "Barking" cough, inspiratory stridor, hoarseness, typically worse at night. Primarily affects the upper airway.
    6. Pertussis (Whooping Cough): Prolonged paroxysmal cough, often followed by a "whooping" sound and post-tussive emesis. Can cause severe pneumonia in infants.
    7. Heart Failure: Tachypnea, cough, poor feeding, hepatomegaly, often in infants with congenital heart disease. CXR may show cardiomegaly and pulmonary edema.
    8. Pulmonary Edema: Can result from fluid overload, acute kidney injury, or cardiac dysfunction.
    9. Pleural Effusion (without underlying pneumonia): Can cause dyspnea and decreased breath sounds, but usually related to other causes (e.g., malignancy, autoimmune disease).
    10. Tuberculosis: Consider in endemic areas or with risk factors, especially for persistent cough, failure to thrive, or abnormal CXR.
    Medical Management for Pediatric Pneumonia

    Aims: The medical management of pediatric pneumonia aims to eradicate the causative pathogen, alleviate symptoms, prevent complications, and provide supportive care tailored to the child's age and severity of illness.

    I. General Principles of Management
    1. Assessment of Severity: The initial step is to assess the severity of pneumonia to determine the appropriate level of care (outpatient vs. inpatient, general ward vs. ICU). Key indicators include respiratory distress (tachypnea, retractions, grunting, nasal flaring), hypoxemia (SpO2 < 90-92%), inability to feed, lethargy, and signs of dehydration.
    2. Empiric Antibiotic Therapy:
      • Rationale: While viral etiologies are common, bacterial pneumonia can be severe and life-threatening. Clinical signs often overlap, and rapid viral testing may not be immediately available. Therefore, empiric antibiotic treatment is crucial, especially in moderate to severe cases, to cover likely bacterial pathogens.
      • De-escalation: Once a pathogen is identified (e.g., strong evidence of viral infection) or if the child rapidly improves, antibiotics may be discontinued or narrowed.
    3. Supportive Care: This is the cornerstone of management for all types of pneumonia (viral and bacterial) and focuses on maintaining oxygenation, hydration, nutrition, and comfort.
    II. Specific Management Strategies
    A. Antimicrobial Therapy (Based on your provided text and general guidelines):

    The choice of antibiotic depends on the child's age, severity of illness, local resistance patterns, and immunization status.

    1. For Infants under 2 months with Severe Pneumonia (Hospitalized):
      • First-line combination: Ampicillin (150-200 mg/kg/day in divided doses IV) plus Gentamycin (5-6 mg/kg/day IV).
        • Rationale: Covers common neonatal pathogens like Group B Streptococcus and Gram-negative enteric bacilli.
      • Alternative if Penicillin Not Available/Suitable: Cefotaxime (IV).
      • If Condition Does Not Improve/Suspicion of S. aureus: Add Cloxacillin (IV) to cover Staphylococcus aureus.
      • Duration: Typically 10 days, but can be individualized based on clinical response and pathogen.
    2. For Older Children 2 months to 5 years (Hospitalized with Severe Pneumonia):
      • First-line: Ceftriaxone (IV, 50-100 mg/kg/day once daily) or Ampicillin plus Gentamycin.
        • Rationale: Ceftriaxone provides broad-spectrum coverage against Streptococcus pneumoniae and Haemophilus influenzae. Ampicillin + Gentamycin is an alternative.
      • Consideration for Atypical Pathogens (e.g., Mycoplasma): If atypical pneumonia is suspected (e.g., persistent cough, gradual onset, older child), a macrolide (e.g., Azithromycin) may be added or used alone depending on clinical suspicion and local guidelines.
      • Duration: Typically 7-10 days.
    3. For Children with Non-Serious Pneumonia (Outpatient Management):
      • First-line: Amoxicillin (oral, 80-90 mg/kg/day divided twice daily).
        • Rationale: Effective against Streptococcus pneumoniae, the most common bacterial cause in this age group, and has a good safety profile.
      • Alternative if Amoxicillin Allergy or Suspected Atypical Pathogen: Macrolide (e.g., Azithromycin, Erythromycin) may be considered.
      • Duration: Typically 5-7 days for uncomplicated cases.
    B. Symptomatic Management and Supportive Care:
    1. Fever Management:
      • Paracetamol (Acetaminophen): Administer for fever (and pain) as per weight-based dosing.
      • Tepid Sponging: Can be used as an adjunctive measure if the child is uncomfortable or has very high fever, but should not be the sole method of fever reduction and can cause discomfort.
      • Goal: Improve comfort and reduce metabolic demands, not necessarily to normalize temperature.
    2. Respiratory Support:
      • Positioning: Nurse patient in a semi-sitting up position or with the head elevated to aid breathing and improve lung expansion.
      • Airway Clearance:
        • Nasal Irrigation: With 0.9% sodium chloride to clear nasal passages, especially important in neonates and infants who are obligate nasal breathers.
        • Assisted Coughing/Suctioning: If the child is unable to clear secretions effectively. Suctioning should be performed gently and only when necessary to avoid trauma or laryngospasm.
        • Chest Physiotherapy (CPT) / Chest Exercises: Can be helpful, especially in cases with significant secretions or atelectasis, but evidence for routine use in uncomplicated pneumonia is mixed.
      • Monitoring for Increased Respiratory Distress: Continuous assessment of respiratory rate, work of breathing, and oxygen saturation is paramount.
      • Bronchodilators: Administer bronchodilators (e.g., inhaled salbutamol) if there is evidence of bronchospasm or significant wheezing, especially in children with a history of asthma or bronchiolitis.
      • Oxygen Therapy:
        • Indication: Administer oxygen where hypoxemia (SpO2 < 90-92% on room air) or cyanosis has occurred.
        • Delivery Methods: Nasal cannula, oxygen mask, high-flow nasal cannula (HFNC) for more severe cases.
        • Goal: Maintain SpO2 > 90-92% (or higher, depending on clinical scenario).
    3. Fluid and Nutritional Support:
      • Hydration: Promote adequate rehydration.
        • Oral Fluids: Encourage frequent sips of oral fluids (water, breast milk, rehydration solutions) as tolerated.
        • Intravenous (IV) Fluids: In children with severe respiratory difficulty, vomiting, or inability to take oral fluids, place an IV line and give fluids cautiously. Typically, start with 70-80% of normal maintenance fluids to avoid fluid overload, which can worsen pulmonary edema. Resume oral fluids as soon as possible.
      • Nutrition:
        • Breastfeeding on Demand: For infants, if they are able to suck effectively and without severe respiratory distress. Breast milk provides vital antibodies and nutrients.
        • Well-Balanced Nutrition: For older children. If oral intake is poor due to dyspnea or fatigue, nasogastric tube (NGT) feeding may be necessary to ensure adequate caloric and fluid intake.
    C. General Care and Monitoring:
    1. Observations: Regular and frequent monitoring of respiratory rate, temperature, heart rate, and oxygen saturation is essential to assess response to treatment and detect deterioration.
    2. Hygiene: Maintain good personal and environmental hygiene to prevent further infections and transmission.
    3. Keep Patient Warm and Dry: Ensure comfortable body temperature and clean, dry clothing/bedding.
    4. Change Position: Regularly change the patient's position to prevent skin breakdown, promote lung expansion, and facilitate secretion drainage.
    5. Rest: Provide adequate rest periods to conserve the child's energy.
    6. Pain Management: Treat any associated pain (e.g., pleuritic chest pain) with analgesics like paracetamol or ibuprofen.
    Nursing Diagnoses for Pediatric Pneumonia

    These diagnoses guide the nurse in identifying patient needs and planning individualized care.

    1. Ineffective Airway Clearance related to increased tracheobronchial secretions, ineffective cough (especially in young children), and inflammation, as evidenced by adventitious breath sounds (crackles, rhonchi), ineffective or absent cough, nasal flaring, tachypnea, dyspnea, pallor/cyanosis, poor feeding.
    2. Impaired Gas Exchange related to alveolar-capillary membrane changes (inflammation, exudate), ventilation-perfusion mismatch, as evidenced by tachypnea, dyspnea, hypoxemia (SpO2 < 90-92%), cyanosis, restlessness/irritability/lethargy, abnormal blood gases.
    3. Ineffective Breathing Pattern related to inflammation, pain (pleuritic), and fatigue, as evidenced by tachypnea, dyspnea, use of accessory muscles, shallow respirations, retractions, grunting.
    4. Risk for inadequate Fluid Volume related to fever, increased insensible fluid loss (tachypnea), decreased oral intake, and vomiting, as evidenced by dry mucous membranes, decreased urine output, poor skin turgor, sunken fontanelles (infants), absent tears.
    5. Inadequate protein energy intake related to anorexia, dyspnea, fatigue, increased metabolic needs, and difficult feeding, as evidenced by reported inadequate intake, weight loss/poor weight gain, refusal to eat/drink, fatigue during feeding.
    6. Hyperthermia related to infectious process and increased metabolic rate, as evidenced by elevated body temperature, flushed skin, tachycardia, tachypnea, irritability.
    7. Acute Pain related to inflammation of lung parenchyma/pleura or generalized body aches, as evidenced by verbal reports of pain (older child), grimacing, guarding, restlessness, crying, irritability, withdrawal.
    8. Activity Intolerance related to imbalance between oxygen supply and demand, generalized weakness, and fatigue, as evidenced by verbal reports of fatigue (older child), decreased play/activity, exertional dyspnea, abnormal heart rate/blood pressure response to activity.
    9. Excessive Anxiety (Child/Parent) related to dyspnea, threat to health status, hospitalization, unfamiliar environment, and fear of unknown outcomes, as evidenced by restlessness, crying, apprehension, irritability, verbalization of concerns.
    10. Inadequate Health Knowledge (Parents) related to disease process, treatment regimen, home care, and prevention, as evidenced by questions, inaccurate follow-through of instructions, verbalization of concerns.
    Specific Nursing Interventions for Pediatric Pneumonia

    These interventions are tailored to the child's age and developmental stage, focusing on gentle, non-threatening approaches.

    A. For Ineffective Airway Clearance / Impaired Gas Exchange / Ineffective Breathing Pattern:
    Intervention Detail/Rationale
    1. Continuous Respiratory Assessment Monitor respiratory rate, depth, rhythm, effort (retractions, nasal flaring, grunting), breath sounds, SpO2 (continuous pulse oximetry is often used), skin color (for cyanosis) every 1-4 hours or more frequently as needed.
    2. Positioning Place the child in a semi-Fowler's position (head of bed elevated 30-45 degrees) or position of comfort to promote lung expansion. Avoid positions that might impede breathing.
    3. Airway Management
    • Nasal Care: Perform nasal saline irrigation and gentle suctioning, especially before feeds and sleep, for infants and young children to clear nasal passages.
    • Encourage Coughing: For older children, encourage deep breathing and effective coughing. For younger children, provide chest physiotherapy (percussion, vibration) as prescribed, followed by suctioning or assisted coughing if appropriate, to mobilize secretions.
    • Suctioning: Perform gentle nasopharyngeal or oropharyngeal suctioning only when necessary to remove visible secretions that the child cannot clear. Use appropriate catheter size and technique to avoid trauma.
    4. Oxygen Therapy
    • Administer warmed, humidified oxygen via nasal cannula, mask, hood, or tent as prescribed, to maintain SpO2 > 90-92%.
    • Monitor oxygen flow rate and ensure patency of delivery device.
    • Minimize crying and agitation to conserve oxygen.
    5. Administer Medications Give bronchodilators, antibiotics, and other prescribed respiratory medications (e.g., corticosteroids) on time and monitor for effectiveness and side effects.
    6. Maintain Hydration Ensure adequate hydration to thin secretions. (See Fluid and Nutrition section).
    B. For Risk for Inadequate Fluid Volume / Inadequate protein energy intake:
    Intervention Detail/Rationale
    1. Monitor Fluid Balance Strictly monitor intake (oral, IV, NGT) and output (urine, stools, emesis). Assess for signs of dehydration (e.g., dry mucous membranes, sunken fontanelles, poor skin turgor, decreased urine output).
    2. Promote Hydration
    • Oral: Offer small, frequent amounts of preferred clear fluids (e.g., Pedialyte, water, diluted juice). For infants, encourage frequent, shorter breastfeeds or formula feeds if tolerated.
    • IV Fluids: Administer IV fluids as prescribed, monitoring for signs of overhydration (e.g., crackles, edema).
    3. Optimize Nutrition
    • Small, Frequent Meals: Offer small, frequent, nutrient-dense meals or snacks.
    • Rest Before Feeds: Allow rest periods before feeding to conserve energy.
    • NGT/OGT Feeding: If the child has significant respiratory distress, is unable to feed orally, or is losing weight, administer feeds via nasogastric or orogastric tube as prescribed.
    • Consult Dietitian: For specialized nutritional assessment and planning.
    C. For Hyperthermia / Acute Pain:
    Intervention Detail/Rationale
    1. Monitor Temperature Assess temperature regularly.
    2. Fever Management
    • Administer antipyretics (e.g., Paracetamol, Ibuprofen) as prescribed, ensuring correct dose based on weight.
    • Remove excessive clothing, use lightweight blankets.
    • Tepid sponging may be used if the child is uncomfortable, but avoid chilling.
    3. Pain Assessment Use age-appropriate pain scales (e.g., FLACC scale for non-verbal children, Faces Pain Scale for older children).
    4. Pain Management
    • Administer analgesics (e.g., Paracetamol, Ibuprofen) as prescribed.
    • Utilize non-pharmacological methods: comfort positioning, distraction (toys, stories, music), parental presence, gentle touch.
    D. For Activity Intolerance:
    Intervention Detail/Rationale
    1. Balance Rest and Activity Organize care to allow for uninterrupted rest periods.
    2. Encourage Age-Appropriate Activity Gradually increase activity as tolerated, monitoring for signs of fatigue or respiratory distress.
    3. Assist with ADLs Provide assistance with activities of daily living as needed to conserve energy.
    E. For Excessive Anxiety (Child/Parent):
    Intervention Detail/Rationale
    1. Child
    • Provide a calm, reassuring presence.
    • Use age-appropriate language to explain procedures.
    • Allow comfort items (e.g., blanket, toy) and parental presence.
    • Use distraction techniques during procedures.
    2. Parents
    • Provide clear, consistent information about the child's condition, treatment plan, and prognosis.
    • Answer questions honestly and empathetically.
    • Encourage participation in care, as appropriate.
    • Address their fears and concerns, and provide emotional support.
    • Refer to social work or spiritual care if needed.
    F. For Inadequate Health Knowledge (Parents):
    Intervention Detail/Rationale
    1. Assess Learning Needs Determine what parents already know and what information they need.
    2. Educate on
    • Disease Process: What pneumonia is, what to expect during recovery.
    • Medications: Name, purpose, dose, frequency, side effects, importance of completing full antibiotic course.
    • Home Care: How to manage fever, cough, recognize worsening symptoms, return precautions (when to seek medical attention).
    • Nutrition and Hydration: Importance of maintaining intake, encouraging small, frequent feeds.
    • Prevention: Hand hygiene, avoiding sick contacts, importance of immunizations (influenza, PCV, Hib).
    • Follow-up: Importance of follow-up appointments.
    3. Teach-Back Method Have parents demonstrate or verbalize understanding of key information.
    4. Provide Written Materials For reinforcement.
    Prevention Strategies for Pediatric Pneumonia

    Effective prevention can significantly reduce the global burden of this disease.

    I. Vaccination

    Vaccines are one of the most effective tools in preventing severe pneumonia and its complications in children.

    1. Pneumococcal Conjugate Vaccine (PCV):
      • Targets: Streptococcus pneumoniae, the leading bacterial cause of pneumonia, meningitis, and sepsis in children.
      • Impact: Dramatically reduced the incidence of invasive pneumococcal disease and pneumonia in vaccinated children and, through herd immunity, in unvaccinated individuals.
      • Recommendation: Universal vaccination for infants, typically administered in a series of doses (e.g., PCV13, PCV15, PCV20 depending on national guidelines).
    2. Haemophilus influenzae type b (Hib) Vaccine:
      • Targets: Haemophilus influenzae type b, another significant bacterial cause of pneumonia, meningitis, and epiglottitis.
      • Impact: Led to a near elimination of invasive Hib disease in vaccinated populations.
      • Recommendation: Universal vaccination for infants, typically administered in a series of doses.
    3. Influenza (Flu) Vaccine:
      • Targets: Seasonal influenza viruses (Type A and B), which can directly cause viral pneumonia or predispose to secondary bacterial pneumonia.
      • Impact: Reduces the risk of influenza illness, hospitalizations, and deaths.
      • Recommendation: Annual vaccination for all children 6 months of age and older, especially those with underlying chronic conditions.
    4. Measles, Mumps, Rubella (MMR) Vaccine:
      • Targets: Measles virus, which can cause severe pneumonia directly and also predispose to secondary bacterial pneumonia due to its immunosuppressive effects.
      • Impact: Significantly reduced measles-associated pneumonia and mortality.
      • Recommendation: Universal vaccination for children.
    5. Pertussis (Whooping Cough) Vaccine (DTaP/Tdap):
      • Targets: Bordetella pertussis, which can cause severe pneumonia, especially in unvaccinated infants.
      • Impact: Reduces the incidence and severity of pertussis.
      • Recommendation: Universal vaccination for infants and booster doses for older children/adolescents. Tdap is also recommended for pregnant women to provide passive immunity to newborns.
    6. Respiratory Syncytial Virus (RSV) Immunization (Passive):
      • Targets: RSV, the leading cause of bronchiolitis and pneumonia in infants.
      • Palivizumab (Synagis): A monoclonal antibody given monthly during RSV season to high-risk infants (e.g., premature infants, those with chronic lung disease, significant congenital heart disease).
      • Newer options: Maternal RSV vaccine and longer-acting monoclonal antibodies are emerging.
      • Impact: Reduces the severity and hospitalization rates due to RSV in vulnerable infants.
    II. Improved Nutrition

    Malnutrition significantly impairs the immune system, making children more susceptible to infections, including pneumonia, and increasing the severity of illness.

    1. Exclusive Breastfeeding: For the first 6 months of life, breast milk provides essential antibodies and immune factors that protect infants from respiratory infections.
    2. Appropriate Complementary Feeding: After 6 months, introduce nutritious, age-appropriate complementary foods alongside continued breastfeeding up to 2 years and beyond.
    3. Adequate Overall Nutrition: Ensure children receive a balanced diet rich in vitamins and minerals to support a robust immune system. Addressing micronutrient deficiencies (e.g., Vitamin A, Zinc) can also be important.
    III. Environmental and Hygiene Measures

    Reducing exposure to pathogens and irritants is critical for preventing pneumonia.

    1. Improved Indoor Air Quality:
      • Reduce Exposure to Indoor Air Pollution: Promote the use of clean cooking fuels and improved cooking stoves to reduce exposure to biomass fuel smoke.
      • Avoid Tobacco Smoke Exposure: Strict avoidance of passive (secondhand) smoke exposure from parents/caregivers, as it irritates airways, impairs ciliary function, and increases susceptibility to respiratory infections.
    2. Good Hand Hygiene:
      • Frequent Handwashing: Educate children and caregivers on the importance of frequent and thorough handwashing with soap and water, especially after coughing/sneezing, before eating, and after using the toilet.
    3. Reduce Crowding: Minimizing overcrowding, especially in daycare settings or households, can reduce the transmission of respiratory pathogens.
    4. Clean Water and Sanitation: Access to clean water and adequate sanitation can indirectly prevent infections that weaken the immune system.
    IV. Health Promotion and Access to Care
    1. Early Recognition and Treatment of Illnesses: Promptly seek medical attention for respiratory symptoms to prevent progression to severe pneumonia.
    2. Management of Underlying Conditions: Effectively manage chronic conditions like asthma, cystic fibrosis, and congenital heart disease, which predispose children to pneumonia.
    3. HIV Prevention and Treatment: In regions with high HIV prevalence, preventing mother-to-child transmission and ensuring access to antiretroviral therapy for children with HIV are crucial, as HIV-positive children are at much higher risk of severe and recurrent pneumonia.
    4. Community Health Programs: Implement and support community-based health programs that promote child health, provide education, and improve access to primary healthcare services, especially in underserved areas.
    5. Antibiotic Stewardship: While a treatment strategy, responsible antibiotic use also plays a role in prevention by limiting the development of antibiotic-resistant bacteria, which could make future pneumonia harder to treat.

    Pneumonia in Children Read More »

    Asthma in children

    Asthma in Children

    Paediatric Asthma Lecture Notes
    Paediatric Asthma

    Asthma is a chronic reversible inflammatory disease of the airways characterized by an obstruction of airflow.

    Asthma can be defined as:

    • A chronic inflammatory disorder of the airways.
    • Characterized by airway hyperresponsiveness (AHR), leading to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.
    • These episodes are associated with widespread, but variable, airflow obstruction within the lung that is often reversible spontaneously or with treatment.

    In simpler terms, a child with asthma has airways that are always a bit "twitchy" or sensitive (inflammatory), making them overreact to various triggers. When they react, the airways narrow, causing the typical asthma symptoms. This narrowing is usually temporary and can be relieved.

    • Inflammation causes recurrent typical characteristics of recurrent episodes of wheezing(occurs during expiration), breathlessness, chest tightness, and coughing, which respond to treatment with bronchodilators.
    • Many inflammatory mediators play a role; mast cells, eosinophils, T-lymphocytes, macrophages, neutrophils, and epithelial cells.
    • No precise cause but genetic and triggers are associations
    Pathophysiology in Children

    The pathophysiology of asthma involves a complex interplay of genetic predisposition, environmental exposures, and immunological responses that lead to characteristic changes in the airways.

  • Airway Inflammation: This is the central and most important feature of asthma. The airways of children with asthma are chronically inflamed, even when they are asymptomatic.
    • Immune Cells Involved:
      • Eosinophils: Key inflammatory cells, recruited to the airways, releasing mediators that damage epithelial cells and contribute to bronchoconstriction.
      • Mast Cells: Reside in the airway mucosa; when activated by allergens or other stimuli, they release potent bronchoconstrictive and inflammatory mediators (e.g., histamine, leukotrienes, prostaglandins).
      • T-lymphocytes (Th2 cells): Predominantly involved in allergic asthma, producing cytokines (e.g., IL-4, IL-5, IL-13) that promote B-cell production of IgE, eosinophil differentiation and survival, and mucus production.
      • Macrophages & Neutrophils: Also contribute to the inflammatory process, especially in severe asthma or in asthma triggered by viral infections.
    • Structural Changes: Chronic inflammation can lead to remodeling of the airway wall over time, including:
      • Epithelial damage/shedding: Increases airway sensitivity.
      • Subepithelial fibrosis: Thickening of the basement membrane.
      • Smooth muscle hypertrophy and hyperplasia: Increase in the size and number of smooth muscle cells, contributing to greater airway narrowing.
      • Mucus gland hyperplasia and hypersecretion: Leads to excessive, tenacious mucus production that can plug airways.
      • Angiogenesis: Formation of new blood vessels, contributing to airway edema.
  • Airway Hyperresponsiveness (AHR):
    • This refers to the exaggerated bronchoconstrictor response of the airways to various stimuli that would cause little or no effect in healthy individuals.
    • It's a consequence of the underlying inflammation and structural changes. The smooth muscle cells contract more easily and forcefully.
    • Common stimuli include allergens, irritants (smoke, fumes), cold air, exercise, viral infections, and certain chemicals.
  • Reversible Airflow Obstruction: During an asthma exacerbation, several factors lead to narrowing of the airways:
    • Bronchoconstriction: Contraction of the airway smooth muscle, rapidly reducing the airway lumen.
    • Airway Edema: Swelling of the airway walls due to inflammation and increased vascular permeability.
    • Increased Mucus Production and Plugging: Thick, tenacious mucus can further block smaller airways.
    • This obstruction causes characteristic symptoms like wheezing (due to air trying to pass through narrowed airways), shortness of breath, and cough.
    • The reversibility (either spontaneously or with bronchodilator medication) is a hallmark feature distinguishing asthma from other obstructive lung diseases.
  • Summary

    The pathophysiology in asthma is reversible and airway inflammation leads to airway narrowing.

    • Trigger Factor. When a person is exposed to a trigger, it causes airway inflammation and mast cells are activated.
    • Activation. When the mast cells are activated, it releases several chemicals called mediators. These chemicals perpetuate the inflammatory response, causing increased blood flow, vasoconstriction, hypersecretion of mucus, the attraction of white blood cells to the area, airway muscle constriction and bronchoconstriction.
    • Narrow Breathing Passages. Acute bronchoconstriction due to allergens results from a release of mediators from mast cells that directly contract the airway.
    • Asthma features: As asthma becomes more persistent, the inflammation progresses and other factors may be involved in the airflow limitation, Signs include wheezing, cough, dyspnea, chest tightness. etc.
    Asthma Phenotypes in Children

    It's important to recognize that asthma isn't a single disease but rather a syndrome with different presentations, especially in children:

    1. Early-Onset (Viral-Induced) Wheezing/Asthma:
      • Often triggered by viral respiratory infections (e.g., RSV, rhinovirus) in infancy and early childhood.
      • May not involve significant allergic sensitization.
      • Many children with viral-induced wheezing "grow out of it" by school age, but a subset will go on to develop persistent asthma.
      • This phenotype is often characterized by neutrophilic inflammation.
    2. Allergic (Atopic) Asthma:
      • The most common phenotype in older children and adults.
      • Strong association with atopy (a genetic predisposition to develop allergic reactions), often coexisting with eczema and allergic rhinitis.
      • Triggered by exposure to common allergens (e.g., dust mites, pollen, pet dander).
      • Characterized by eosinophilic inflammation and IgE-mediated responses.
      • Often persists into adulthood.
    3. Other Phenotypes: Less common but include exercise-induced bronchoconstriction, occupational asthma, and severe asthma that is difficult to control.
    Asthma Severity Classification (Levels of Asthma)

    The Global Initiative for Asthma (GINA) guidelines, widely used internationally, classify asthma into categories based on symptom frequency, nocturnal awakenings, reliever use, and interference with normal activity. Lung function measurements (FEV1 and FEV1/FVC ratio) are also considered for older children capable of performing spirometry.

    1. Intermittent Asthma: Asthma is considered intermittent if without treatment any of the following are true:
      • Daytime symptoms: ≤ 2 days per week.
      • Nighttime awakenings: ≤ 2 times per month.
      • Reliever (SABA) use: ≤ 2 days per week.
      • Interference with normal activity: None.
      • Exacerbations: Infrequent, usually mild.
      • Lung Function (for children > 5 years capable of spirometry):
        • FEV1 > 80% predicted.
        • FEV1/FVC: Normal.
      • Recommendation: No daily controller medication is typically needed, but a short-acting beta-agonist (SABA) is used for quick relief of symptoms.
    2. Mild Persistent Asthma: Asthma is considered mild persistent if without treatment any of the following are true:
      • Daytime symptoms: > 2 days per week but not daily.
      • Nighttime awakenings: 3-4 times per month.
      • Reliever (SABA) use: > 2 days per week but not daily.
      • Interference with normal activity: Minor limitation.
      • Exacerbations: May affect activity.
      • Lung Function (for children > 5 years):
        • FEV1 > 80% predicted.
        • FEV1/FVC: Normal.
      • Recommendation: Requires daily low-dose inhaled corticosteroid (ICS) or a leukotriene receptor antagonist (LTRA) as a controller medication, in addition to SABA for quick relief.
    3. Moderate Persistent Asthma: Asthma is considered moderate persistent if without treatment any of the following are true:
      • Daytime symptoms: Daily.
      • Nighttime awakenings: > 1 time per week but not nightly.
      • Reliever (SABA) use: Daily.
      • Interference with normal activity: Some limitation.
      • Exacerbations: May require oral corticosteroids.
      • Lung Function (for children > 5 years):
        • FEV1 60-80% predicted.
        • FEV1/FVC: Reduced by 5%.
      • Recommendation: Requires daily low-to-medium dose ICS plus a long-acting beta-agonist (LABA), or medium-dose ICS, in addition to SABA for quick relief.
    4. Severe Persistent Asthma: Asthma is considered severe persistent if without treatment any of the following are true:
      • Daytime symptoms: Continual.
      • Nighttime awakenings: Often nightly.
      • Reliever (SABA) use: Several times per day.
      • Interference with normal activity: Extreme limitation.
      • Exacerbations: Frequent, may require oral corticosteroids, hospitalizations.
      • Lung Function (for children > 5 years):
        • FEV1 < 60% predicted.
        • FEV1/FVC: Reduced by > 5%.
      • Recommendation: Requires daily high-dose ICS plus LABA and, potentially, oral corticosteroids, or other advanced therapies (e.g., biologics), in addition to SABA for quick relief.
    Risk Factors for Developing Asthma

    These are factors that increase a child's susceptibility to developing asthma. They often represent a combination of genetic predisposition and early-life environmental exposures.

    1. Genetic Predisposition/Family History:
      • Atopy: The strongest identifiable risk factor. Atopy is a genetic tendency to develop allergic diseases (asthma, allergic rhinitis, eczema). Children with a personal history of atopic dermatitis (eczema) or allergic rhinitis are at significantly higher risk for asthma.
      • Parental Asthma: Children with one asthmatic parent have a 2-3 fold increased risk of developing asthma; if both parents have asthma, the risk is even higher (up to 6-fold). This highlights the strong hereditary component.
    2. Environmental Exposures in Early Life:
      • Exposure to Tobacco Smoke:
        • Maternal Smoking during Pregnancy: Increases the risk of wheezing and asthma in offspring, potentially due to altered lung development.
        • Secondhand Smoke Exposure (Passive Smoking): A well-established risk factor for developing asthma and a major trigger for exacerbations. It irritates airways, impairs lung growth, and increases susceptibility to respiratory infections.
      • Early Life Viral Respiratory Infections:
        • Respiratory Syncytial Virus (RSV) and Rhinovirus: Severe infections, especially in infancy, are strongly associated with recurrent wheezing and an increased risk of developing persistent asthma, particularly in genetically susceptible individuals.
        • The link is complex; these infections might unmask underlying airway hyperresponsiveness or contribute to airway remodeling.
      • Allergen Exposure:
        • Early sensitization to perennial indoor allergens: (e.g., house dust mites, pet dander from cats/dogs, cockroaches) can contribute to the development of allergic asthma, especially in genetically predisposed children.
        • The "hygiene hypothesis" suggests that reduced exposure to certain microbes in early life might shift the immune system towards an allergic (Th2) response.
      • Air Pollution: Exposure to outdoor air pollutants (e.g., particulate matter, ozone, nitrogen dioxide from traffic) can increase the risk of asthma development and exacerbations.
    3. Other Factors:
      • Low Birth Weight/Prematurity: Premature infants, especially those with bronchopulmonary dysplasia (BPD), have a higher risk of developing recurrent wheezing and asthma-like symptoms.
      • Obesity: Growing evidence suggests a link between childhood obesity and an increased risk of developing asthma, particularly non-allergic phenotypes.
      • Gastroesophageal Reflux Disease (GERD): While GERD can be a trigger for existing asthma, severe or chronic GERD in infancy may also be a risk factor for developing respiratory symptoms.
      • Sex: Before puberty, boys are more likely to have asthma than girls. This trend often reverses after puberty.
    Triggers for Asthma Exacerbations

    Triggers are specific stimuli that can cause airways to narrow and provoke asthma symptoms in a child who already has asthma. Identifying and avoiding these triggers is a cornerstone of asthma management.

  • Allergens:
    • Indoor Allergens:
      • House Dust Mites: Found in bedding, carpets, upholstered furniture.
      • Pet Dander: From cats, dogs, birds, rodents.
      • Cockroach Allergens: Found in droppings and body parts, especially in urban environments.
      • Molds: Indoors (damp areas like bathrooms) and outdoors.
    • Outdoor Allergens:
      • Pollen: From trees, grasses, weeds (seasonal).
  • Irritants:
    • Tobacco Smoke: Both secondhand and thirdhand smoke (residue on surfaces).
    • Air Pollution: Outdoor pollutants (ozone, particulate matter, sulfur dioxide, nitrogen dioxide).
    • Strong Odors/Fumes: Perfumes, cleaning products, paint fumes, deodorizers, cooking odors.
    • Chemical Sprays: Hair spray, aerosols.
    • Wood Smoke/Fireplace Smoke.
    • Dust: General household dust (distinct from dust mite allergen).
  • Respiratory Infections:
    • Viral Infections: The most common trigger for asthma exacerbations in children, especially in infants and preschoolers. Viruses like rhinovirus (common cold), RSV, influenza, and parainfluenza can cause significant airway inflammation and trigger wheezing episodes.
    • Bacterial Infections: Less common as direct triggers, but can sometimes lead to exacerbations.
  • Exercise:
    • Exercise-Induced Bronchoconstriction (EIB): Occurs when airways narrow during or after physical activity, often exacerbated by cold, dry air. It is a common manifestation of asthma, not a separate condition, but can also occur in non-asthmatic individuals.
  • Weather Changes / Meteorological Factors:
    • Cold Air: Can directly irritate and narrow airways.
    • Changes in Temperature or Humidity.
    • Thunderstorms: Can worsen asthma, possibly by increasing airborne allergen levels (e.g., pollen fragments).
  • Emotional Factors / Stress:
    • Strong Emotions: Crying, laughing, anger, anxiety, stress can sometimes trigger or worsen asthma symptoms, likely through vagal nerve stimulation or changes in breathing patterns.
  • Gastroesophageal Reflux Disease (GERD):
    • Acid reflux into the esophagus can indirectly trigger bronchoconstriction through vagal reflexes or microaspiration into the airways.
  • Certain Medications:
    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): (e.g., ibuprofen, aspirin) can trigger asthma in a small subset of sensitive individuals (aspirin-exacerbated respiratory disease, AERD).
    • Beta-blockers: (even eye drops) can worsen asthma by causing bronchoconstriction.
  • Clinical Presentation of Asthma in Children

    The clinical presentation of asthma in children is highly variable, influenced by the child's age, the severity of the asthma, and the specific triggers involved. It's often referred to as "the great masquerader" because its symptoms can overlap with other common childhood respiratory illnesses.

    I. Cardinal Symptoms of Asthma

    Regardless of age, asthma is primarily characterized by a constellation of recurrent respiratory symptoms, often worse at night or in the early morning, or in response to exercise or other triggers.

    1. Wheezing:
      • A high-pitched, whistling sound produced by air passing through narrowed airways, usually heard on exhalation but can be heard on inhalation in severe cases.
      • It's the most recognized symptom, but its absence does not rule out asthma, especially in young children or during a severe attack (where airflow might be too limited to produce a sound – "silent chest").
    2. Cough:
      • Can be dry, persistent, hacking, or can produce sputum (though less common in young children).
      • Often worse at night, with exercise, or after exposure to triggers.
      • Sometimes, cough is the only symptom, leading to a diagnosis of "cough-variant asthma."
    3. Shortness of Breath (Dyspnea):
      • Difficulty breathing, often described by older children as feeling "winded" or "out of breath."
      • In younger children, this may manifest as rapid breathing (tachypnea) or increased work of breathing.
    4. Chest Tightness:
      • A constricting sensation in the chest, often described by older children as feeling like "an elephant sitting on my chest" or "a band squeezing my chest."
      • Younger children may rub their chest or be irritable.
    Age-Specific Presentations

    The way these cardinal symptoms manifest and are described can differ significantly between infants/toddlers and older children/adolescents.

    A. Infants and Young Children (typically < 5-6 years old):

    Diagnosing asthma in this age group is challenging because:

    • Their airways are smaller and more prone to obstruction.
    • They often have frequent viral infections that cause wheezing, and many "outgrow" this viral-induced wheezing.
    • They cannot verbally describe symptoms.
    • Objective lung function tests are difficult to perform.

    Common Manifestations:

    • Recurrent episodes of wheezing and coughing, often following a viral infection (e.g., "always getting colds that go to their chest").
    • Persistent cough, especially at night or with activity.
    • Increased work of breathing:
      • Tachypnea (rapid breathing).
      • Nasal flaring.
      • Retractions: Sucking in of skin between ribs (intercostal), below ribs (subcostal), or above clavicles (supraclavicular/substernal).
      • Grunting: A short, low sound heard at the end of exhalation, indicating partial closure of the glottis to maintain lung volume.
      • Head bobbing (in severe cases).
    • Feeding difficulties: Interruptions in feeding due to breathlessness.
    • Irritability and restlessness: Due to hypoxemia and respiratory distress.
    • Fatigue or lethargy: In severe cases.
    • Prolonged expiratory phase.
    B. Older Children and Adolescents (typically > 5-6 years old):

    In this age group, symptoms become more similar to adult asthma and they are better able to communicate their symptoms.

    • Classic Symptoms: Recurrent wheezing, coughing, shortness of breath, chest tightness.
    • Exercise-Induced Symptoms: Cough, wheezing, or shortness of breath that starts during or shortly after physical activity. This is a very common presentation in this age group.
    • Nocturnal Symptoms: Symptoms that wake them from sleep (cough, wheezing, dyspnea).
    • Seasonal Patterns: Symptoms worsening during specific seasons (e.g., pollen season).
    • Symptoms after exposure to specific triggers: (e.g., pets, dust, smoke).
    • Decreased activity or avoidance of sports due to breathlessness.
    • Poor performance in school (due to nocturnal symptoms or exacerbations).
    Asthma Exacerbations (Asthma Attacks)

    An asthma exacerbation is an acute or subacute episode of progressively worsening shortness of breath, cough, wheezing, or chest tightness, or a combination of these symptoms.

  • Signs of a Mild-to-Moderate Exacerbation:
    • Increased respiratory rate.
    • Use of accessory muscles (mild).
    • Audible wheezing.
    • Cough.
    • Children may be anxious.
    • Able to speak in full sentences.
    • Oxygen saturation (SpO2) often > 92-94%.
    • Peak Expiratory Flow (PEF) or FEV1: 50-80% of personal best or predicted.
  • Signs of a Severe Exacerbation (Requires urgent medical attention):
    • Severe dyspnea, child struggles to breathe.
    • Speech limited to single words or phrases.
    • Use of accessory muscles (prominent retractions, sternocleidomastoid use).
    • Loud wheezing, or absent wheezing ("silent chest" - very ominous sign indicating severe airflow obstruction).
    • Cyanosis (bluish discoloration of lips, nail beds) - a late sign of hypoxemia.
    • Confusion, drowsiness, altered consciousness (ominous signs).
    • Tachycardia and possibly bradycardia (in very severe cases).
    • SpO2 < 92%.
    • PEF or FEV1: < 50% of personal best or predicted.
  • Status Asthmaticus: A severe, life-threatening asthma exacerbation that is refractory to standard bronchodilator and corticosteroid therapy. This is a medical emergency requiring aggressive management.
  • Diagnostic Approaches

    The diagnosis of asthma is largely clinical, based on a recurring pattern of respiratory symptoms and response to asthma medications.

    A. Clinical History (The most important component):

    A detailed history should be obtained from the child (if old enough) and caregivers, focusing on:

    1. Symptom Characteristics:
      • Recurrent episodes of wheezing, coughing, shortness of breath, chest tightness.
      • Timing: Worse at night, in the early morning, or seasonally.
      • Triggers: What provokes symptoms (e.g., exercise, cold air, allergens, viral infections, strong odors, emotional stress).
      • Response to Medications: Improvement with bronchodilators (e.g., albuterol/salbutamol).
    2. Family History:
      • Parental history of asthma, allergies, eczema.
      • Siblings with asthma.
    3. Personal History:
      • History of atopic dermatitis (eczema), allergic rhinitis (hay fever).
      • History of viral-induced wheezing in infancy.
      • Recurrent pneumonia or bronchitis.
      • Hospitalizations or emergency department visits for respiratory symptoms.
      • Environmental exposures (tobacco smoke, pets, mold).
    4. Impact on Daily Life:
      • School absences.
      • Limitations on physical activity or sports.
      • Sleep disturbances.
    B. Physical Examination:

    Often normal between exacerbations, but during an exacerbation, findings may include:

    1. Audible Wheezing: On auscultation (inspiration, expiration, or both). Absence of wheezing (silent chest) can be an ominous sign of severe obstruction.
    2. Increased Work of Breathing: Tachypnea, retractions (intercostal, subcostal, supraclavicular), nasal flaring, prolonged expiratory phase.
    3. Cyanosis: Bluish discoloration of lips/nail beds (a late sign of severe hypoxemia).
    4. Tachycardia: Increased heart rate.
    5. Hyperinflation: Barrel chest, especially in chronic, poorly controlled asthma.
    6. Allergic Stigmata: Nasal crease, allergic shiners (dark circles under eyes), pale/boggy nasal mucosa (suggesting allergic rhinitis).
    C. Objective Tests (When feasible):
    1. Spirometry with Bronchodilator Reversibility (for children typically ≥ 5-6 years old):
      • Gold standard for diagnosis and monitoring in cooperative children.
      • Procedure: Measures forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC).
      • Asthma Findings: Obstructive pattern (reduced FEV1, reduced FEV1/FVC ratio).
      • Reversibility: A significant improvement in FEV1 (usually ≥ 12% increase) after administration of a short-acting bronchodilator (e.g., albuterol) confirms reversible airflow obstruction, a hallmark of asthma.
    2. Peak Expiratory Flow (PEF) Monitoring:
      • Measures the maximum speed of exhalation.
      • Can be used at home for daily monitoring of lung function in older children (>5-6 years) to detect worsening asthma and guide management.
      • Less sensitive than spirometry and effort-dependent, but useful for identifying personal best and variability.
    3. Bronchial Provocation Tests (e.g., Methacholine Challenge):
      • Used when asthma is suspected but spirometry is normal and reversibility is absent.
      • Patient inhales increasing doses of a bronchoconstricting agent (e.g., methacholine). A significant drop in FEV1 indicates airway hyperresponsiveness.
      • Usually performed in specialized centers.
    4. Allergy Testing (Skin Prick Test or Specific IgE Blood Test):
      • Identifies specific allergens that trigger symptoms, helping with avoidance strategies.
      • Positive tests support a diagnosis of allergic asthma but do not, by themselves, diagnose asthma.
    5. Fractional Exhaled Nitric Oxide (FeNO):
      • Measures the level of nitric oxide in exhaled breath, which is often elevated in eosinophilic airway inflammation (a type of asthma inflammation).
      • Can be useful as an adjunctive tool in diagnosis and for monitoring response to inhaled corticosteroids.
    6. Therapeutic Trial:
      • In young children (< 5 years) where objective tests are difficult, a diagnosis can sometimes be made based on a significant improvement in symptoms (e.g., reduction in wheezing episodes, cough, improved activity) with a trial of asthma controller medication (e.g., low-dose inhaled corticosteroid).
    Challenges in Diagnosing Asthma in Young Children (<5 years)
    • Non-specific Symptoms: Cough and wheezing are common with viral infections.
    • Difficulty with Objective Tests: Cannot perform spirometry or PEF.
    • "Transient Early Wheezers": Many infants wheeze with viral infections but do not develop chronic asthma.
    • Predictive Indices: The Asthma Predictive Index (API) uses a combination of major (parental asthma, eczema, allergic sensitization) and minor (other allergic conditions, wheezing unrelated to colds) criteria to predict which wheezing infants are more likely to develop persistent asthma.
    Differential Diagnoses for Pediatric Asthma

    It's crucial to rule out other conditions that can cause similar respiratory symptoms.

    1. Infections:
      • Bronchiolitis: (Especially in infants, usually RSV-related).
      • Viral Tracheobronchitis (Croup): Inspiratory stridor, barking cough.
      • Pneumonia: Fever, localized crackles/rhonchi, infiltrates on chest X-ray.
      • Pertussis (Whooping Cough): Paroxysms of coughing followed by inspiratory "whoop."
    2. Upper Airway Obstruction:
      • Foreign Body Aspiration: Sudden onset of coughing, choking, unilateral wheezing. Always consider in any child with new onset or unexplained unilateral wheezing.
      • Laryngomalacia/Tracheomalacia: Stridor, often worse when crying or feeding.
      • Vocal Cord Dysfunction: Paradoxical vocal cord movement leading to inspiratory obstruction.
      • Enlarged Adenoids/Tonsils: Can cause noisy breathing and obstructive sleep apnea.
    3. Congenital/Structural Abnormalities:
      • Cystic Fibrosis (CF): Chronic cough, recurrent infections, failure to thrive, steatorrhea.
      • Congenital Heart Disease: Symptoms of heart failure (tachypnea, poor feeding, sweating with feeds).
      • Tracheoesophageal Fistula/H-type fistula: Recurrent aspiration, coughing with feeds.
      • Bronchopulmonary Dysplasia (BPD): History of prematurity and chronic lung disease.
      • Airway Malformations: Tracheal stenosis, vascular rings.
    4. Gastrointestinal Issues:
      • Gastroesophageal Reflux Disease (GERD): Reflux leading to chronic cough or aspiration.
    5. Immunodeficiency:
      • Recurrent infections, failure to thrive.
    6. Other:
      • Alpha-1 Antitrypsin Deficiency: Rare, but can cause early-onset emphysema.
      • Primary Ciliary Dyskinesia: Chronic sinusitis, bronchiectasis, situs inversus.
    Medical Management Strategies for Pediatric Asthma

    The goal of asthma management in children is to achieve and maintain good asthma control, which means:

    • Minimizing chronic symptoms: Day and night.
    • Preventing severe exacerbations: Reducing emergency room visits and hospitalizations.
    • Maintaining normal (or near-normal) lung function.
    • Maintaining normal activity levels: Including participation in sports and play.
    • Avoiding adverse effects from asthma medications.

    Asthma management is guided by a stepwise approach, where treatment is "stepped up" if control is not achieved and "stepped down" when control is maintained for a period. This approach is personalized and outlined in the child's Asthma Action Plan.

    Key Components of Asthma Management
    1. Patient and Family Education: This is paramount.
      • Understanding asthma (what it is, triggers, goals of treatment).
      • Proper use of inhalers and devices (spacers are critical for children).
      • Recognizing worsening symptoms and knowing when to seek help.
      • Adherence to medication regimens.
      • Development of a personalized Asthma Action Plan.
    2. Environmental Control and Trigger Avoidance:
      • Identifying and reducing exposure to known allergens (dust mites, pet dander, mold, pollen).
      • Eliminating exposure to tobacco smoke (e.g., parental smoking cessation).
      • Avoiding irritants (strong odors, air pollution).
      • Managing co-morbid conditions (e.g., allergic rhinitis, GERD).
    3. Pharmacological Therapy: Medications are generally divided into two main categories:
      • Controller Medications (Preventive): Taken daily, long-term, to reduce airway inflammation and prevent symptoms.
      • Reliever Medications (Quick-Relief): Taken as needed to rapidly open airways and relieve acute symptoms during an exacerbation.
    Pharmacological Therapy: Controller Medications

    These medications are the cornerstone of long-term asthma control, addressing the underlying inflammation.

    1. Inhaled Corticosteroids (ICS):
      • Mechanism: Anti-inflammatory agents that reduce airway inflammation, mucus production, and airway hyperresponsiveness. They are the most effective long-term controller medication for persistent asthma.
      • Examples: Fluticasone, Budesonide, Mometasone, Beclomethasone, Ciclesonide.
      • Delivery: Via metered-dose inhaler (MDI) with a spacer/valved holding chamber (VHC) or nebulizer.
      • Dosing: Taken daily. Doses are categorized as low, medium, or high, based on age and specific product.
      • Side Effects: Generally well-tolerated. Local side effects (oral candidiasis/thrush, dysphonia) can be minimized by using a spacer and rinsing the mouth after use. Systemic effects (e.g., growth suppression) are minimal at recommended doses and outweighed by the benefits of asthma control.
    2. Long-Acting Beta2-Agonists (LABA):
      • Mechanism: Bronchodilators that provide long-lasting (up to 12 hours) relaxation of airway smooth muscle.
      • Examples: Salmeterol, Formoterol.
      • Important Note: LABAs should NEVER be used alone in asthma. They must always be used in combination with an ICS, typically in a single inhaler device (e.g., Fluticasone/Salmeterol, Budesonide/Formoterol). This is because while they relax muscles, they do not treat the underlying inflammation, and monotherapy can lead to worsened outcomes.
      • Role: Added to ICS therapy when asthma is not well-controlled on ICS alone (e.g., moderate persistent asthma).
    3. Leukotriene Receptor Antagonists (LTRAs):
      • Mechanism: Block the action of leukotrienes, inflammatory mediators that contribute to bronchoconstriction, mucus secretion, and airway inflammation.
      • Example: Montelukast (oral tablet/granules).
      • Role: Can be used as an alternative or add-on therapy for mild persistent asthma, especially if there's an allergic component or exercise-induced bronchoconstriction. Also helpful for co-morbid allergic rhinitis. Generally less potent than ICS.
    4. Other Controller Medications (for severe/uncontrolled asthma, used by specialists):
      • Systemic Corticosteroids: Oral prednisone/prednisolone are used for short bursts during severe exacerbations but are not for long-term daily control due to significant systemic side effects. Long-term oral corticosteroids are reserved for the most severe, refractory cases.
      • Immunomodulators/Biologics: (e.g., Omalizumab, Mepolizumab, Reslizumab, Benralizumab) are monoclonal antibodies targeting specific inflammatory pathways (e.g., IgE, IL-5) for children with severe, persistent allergic or eosinophilic asthma not controlled by standard therapy.
      • Cromolyn Sodium/Nedocromil: Mast cell stabilizers, rarely used now due to less efficacy compared to ICS.
    Pharmacological Therapy: Reliever Medications (Quick-Relief)

    These medications provide rapid relief of acute symptoms and are used on an as-needed basis.

    1. Short-Acting Beta2-Agonists (SABAs):
      • Mechanism: Rapidly relax airway smooth muscle, leading to bronchodilation within minutes.
      • Examples: Albuterol (Salbutamol outside the US), Levalbuterol.
      • Delivery: Via MDI with a spacer/VHC or nebulizer.
      • Role: Used for acute symptom relief (wheezing, cough, shortness of breath) during an asthma attack or before exercise (for EIB).
      • Important Note: Frequent SABA use (>2 days/week, not including pre-exercise use) indicates poorly controlled asthma and signals a need to step up controller therapy.
    2. Systemic Corticosteroids (Oral/IV):
      • Mechanism: Powerful anti-inflammatory agents.
      • Role: Used for short courses (e.g., 3-5 days) during moderate to severe asthma exacerbations to reduce airway inflammation and prevent progression to severe lung damage. They are not quick-relief in the same way as SABAs but are critical for resolving inflammation during attacks.
    Stepwise Approach to Management (Simplified)

    This is a general guide, with specific dosages and choices tailored to the individual child.

    • Step 1: Intermittent Asthma: SABA as needed.
    • Step 2: Mild Persistent Asthma: Low-dose ICS daily OR LTRA daily. SABA as needed.
    • Step 3: Moderate Persistent Asthma: Medium-dose ICS daily OR Low-dose ICS + LABA daily. SABA as needed.
    • Step 4: Moderate-Severe Persistent Asthma: Medium-dose ICS + LABA daily OR High-dose ICS daily. SABA as needed.
    • Step 5-6: Severe Persistent Asthma: High-dose ICS + LABA daily, possibly with additional therapies (e.g., LTRA, biologics, oral corticosteroids). SABA as needed.
    Practically,

    General Principles: Stepwise approach based on symptom control. Inhaled route preferred. Use spacers for children/poor technique.

    Reliever Therapy (For symptom relief): Short-Acting Beta2-Agonists (SABA) - e.g., Salbutamol inhaler 100-200mcg (1-2 puffs) PRN.

    Controller Therapy (Regular prevention - based on severity step):

    • Step 1 (Intermittent): SABA PRN only.
    • Step 2 (Mild Persistent): Low-dose Inhaled Corticosteroid (ICS) - e.g., Beclomethasone 100-200mcg BID. Plus SABA PRN.
    • Step 3 (Moderate Persistent): Low-dose ICS + Long-Acting Beta2-Agonist (LABA) - e.g., Salmeterol/Fluticasone or Budesonide/Formoterol combination inhaler OR Medium/High-dose ICS. Plus SABA PRN. (UCG suggests high-dose ICS first). Consider adding Aminophylline 200mg BID (adults - less preferred now).
    • Step 4 (Severe Persistent): High-dose ICS + LABA +/- other controllers (e.g., LTRA, Theophylline, Tiotropium). Consider regular low-dose oral Prednisolone (specialist). Plus SABA PRN.
    Acute Asthma Attack Management:
    • Mild/Moderate (Outpatient/HC3): Salbutamol inhaler (via spacer) 2-10 puffs OR Nebulized Salbutamol 2.5-5mg. Repeat Q20-30min PRN for 1 hour. Oral Prednisolone 1mg/kg (max 50mg) daily for 3-5 days.
    • Severe (Referral/HC4/Hospital): Oxygen (aim SpO2 >94%). High-dose Salbutamol (nebulized or MDI+spacer, repeated frequently). Add Ipratropium Bromide nebulized (250-500mcg) Q20-30min initially. Systemic Corticosteroids (Oral Prednisolone or IV Hydrocortisone 100mg Q6H). Consider IV Aminophylline (loading + infusion - use with caution, specialist input).
    • Life-Threatening (Hospital/ICU): As for Severe, plus consider IV Magnesium Sulphate, potential need for intubation/ventilation.

    Rescue Course Oral Steroids: Short course (3-5 days) of Prednisolone can be used at any step for exacerbations.

    Nursing Diagnoses for Pediatric Asthma

    Nursing diagnoses provide a framework for individualized care based on the child's response to their health condition. Here are some key nursing diagnoses relevant to pediatric asthma:

    1. Ineffective Airway Clearance related to bronchoconstriction, increased mucus production, and airway inflammation, as evidenced by wheezing, cough, dyspnea, abnormal breath sounds, and use of accessory muscles.
      Rationale: Directly addresses the primary physiological impairment in asthma.
    2. Impaired Gas Exchange related to altered oxygen supply (bronchoconstriction, mucous plugging) and alveolar-capillary membrane changes (inflammation) as evidenced by hypoxemia, tachypnea, restlessness, and abnormal blood gas values.
      Rationale: Focuses on the consequence of compromised airway clearance on oxygenation and ventilation.
    3. Ineffective Breathing Pattern related to bronchoconstriction, anxiety, and fear, as evidenced by tachypnea, dyspnea, nasal flaring, retractions, and prolonged expiratory phase.
      Rationale: Addresses the altered mechanics of breathing often seen during an exacerbation.
    4. Activity Intolerance related to imbalance between oxygen supply and demand, and fatigue secondary to increased work of breathing, as evidenced by verbal reports of fatigue, shortness of breath on exertion, and reluctance to participate in age-appropriate activities.
      Rationale: Highlights the impact of asthma on the child's ability to engage in normal life.
    5. Excessive Anxiety (Child and/or Parent) related to acute illness, fear of suffocation, potential for serious complications, and insufficient knowledge of disease process/management, as evidenced by restlessness, irritability, crying, verbalization of concerns, and difficulty sleeping.
      Rationale: Recognizes the emotional toll of a chronic illness and acute exacerbations.
    6. Inadequate Health Knowledge (Child and/or Parent) regarding disease process, triggers, medication regimen, and emergency management, as evidenced by verbalized questions, inaccurate follow-through of instructions, and recurrent exacerbations.
      Rationale: Addresses the critical need for education in managing a chronic condition effectively.
    7. Risk for Ineffective Therapeutic Regimen Management related to complexity of medication schedule, lack of resources, cultural beliefs, or insufficient support systems.
      Rationale: Proactive diagnosis to identify potential barriers to adherence.
    8. Risk for Infection related to compromised respiratory system and altered immune response (especially if on oral steroids).
      Rationale: Children with asthma are often more susceptible to respiratory infections, which are also common triggers.
    Specific Nursing Interventions for Pediatric Asthma
    A. During an Acute Exacerbation:
    Intervention Detail/Rationale
    1. Assess Respiratory Status Frequently
    • Monitor respiratory rate, effort, depth, and rhythm.
    • Auscultate lung sounds for wheezing, diminished breath sounds.
    • Assess for use of accessory muscles, nasal flaring, retractions.
    • Monitor oxygen saturation (SpO2) via pulse oximetry.
    • Assess level of consciousness, restlessness, and anxiety.
    • Evaluate skin color and capillary refill.
    2. Administer Medications as Ordered
    • Bronchodilators (SABAs): Administer via MDI with spacer/VHC or nebulizer. Ensure proper technique and assess response (decreased wheezing, improved SpO2, reduced work of breathing). Monitor for side effects (tachycardia, tremors).
    • Corticosteroids (Oral/IV): Administer as prescribed to reduce inflammation.
    3. Maintain Patent Airway and Optimize Breathing
    • Position child upright or in a position of comfort (e.g., tripod position) to facilitate breathing.
    • Provide supplemental oxygen as ordered to maintain SpO2 > 92-95%.
    • Encourage slow, deep breathing (if age-appropriate).
    • Encourage effective coughing to clear secretions.
    4. Reduce Anxiety (Child and Parents)
    • Maintain a calm environment.
    • Stay with the child, providing reassurance.
    • Explain procedures and what to expect in simple, age-appropriate language.
    • Involve parents in care as much as possible, providing clear updates.
    5. Monitor for Worsening Status
    • Be vigilant for signs of respiratory failure (decreased level of consciousness, cyanosis, bradycardia, absent breath sounds/wheezing, exhaustion).
    • Prepare for potential intubation and mechanical ventilation in severe cases.
    B. For Long-Term Management and Education (Critical Role):
    Intervention Detail/Rationale
    1. Educate on Asthma Pathophysiology and Triggers
    • Explain what asthma is in simple terms (inflammation, bronchoconstriction, mucus).
    • Help identify specific triggers for the child and discuss avoidance strategies (e.g., dust mite control, pet dander reduction, smoking cessation for parents).
    • Emphasize the importance of flu and pneumonia vaccines.
    2. Medication Education
    • Purpose: Differentiate between controller (preventive, daily) and reliever (rescue, as needed) medications.
    • Administration Technique: Demonstrate and have child/parent return-demonstrate proper use of MDIs with spacers, nebulizers, and dry powder inhalers. Emphasize rinsing mouth after ICS.
    • Adherence: Discuss the importance of daily controller medication use even when feeling well.
    • Side Effects: Explain potential side effects and how to manage them.
    3. Asthma Action Plan (AAP) Teaching
    • Review the individualized AAP with child and parents.
    • Ensure understanding of "Green," "Yellow," and "Red" zones, and the corresponding actions.
    • Teach how to recognize early warning signs of an exacerbation.
    • Instruct on when to use reliever medications and when to seek emergency care.
    • If applicable, teach how to use a peak flow meter and interpret readings.
    4. Promote Self-Management Skills
    • Encourage older children to participate in their own care and decision-making.
    • Develop problem-solving skills for managing symptoms at school, during activities, etc.
    5. Support and Resources
    • Provide emotional support and validate fears/concerns.
    • Refer to support groups, asthma camps, and community resources.
    • Advocate for the child's needs at school (e.g., medication administration, reduced physical activity during exacerbations).
    6. Nutritional Support and Hydration
    • Encourage adequate fluid intake to thin secretions (during exacerbations and generally).
    • Address any concerns related to appetite or feeding difficulties.
    7. Monitor Growth and Development
    • Regularly assess growth parameters, especially in children on long-term ICS, although significant growth suppression is rare at therapeutic doses.
    • Monitor for psychosocial impacts of chronic illness.

    Asthma in Children Read More »

    Pericarditis

    Pericarditis

    Pericarditis Lecture Notes
    PERICARDITIS
    Introduction

    Pericarditis is the inflammation of the pericardium, a double-layered sac that encloses the heart and the roots of the great vessels (aorta, pulmonary artery, vena cavae). This sac provides protection, lubrication, and helps to anchor the heart within the chest cavity. When inflamed, the layers of the pericardium can rub against each other, causing characteristic pain and other symptoms.


    The Pericardium

    The pericardium is a thin, two-layered, fluid-filled sac that covers the outer surface of the heart.(normal volume of the fluid is around 50ml)

    • It also prevents the heart from over-expanding when blood volume increases, which keeps the heart functioning efficiently.
    • It shields the heart from infection or malignancy and contains the heart in the chest wall.
    Etiology (Causes) of Pericarditis

    Pericarditis can be caused by various factors, with idiopathic (unknown cause) being the most common, often suspected to be viral in origin.

    Infections:
    • Viral: Most common cause of acute pericarditis (e.g., coxsackievirus, echovirus, influenza, HIV).
    • Bacterial: Less common but more severe (e.g., tuberculosis, staphylococcal, streptococcal).
    • Fungal and Parasitic: Rare, typically in immunocompromised individuals.
    Other Causes:
    • Autoimmune Diseases: Systemic inflammatory conditions like Systemic Lupus Erythematosus (SLE), rheumatoid arthritis, scleroderma, and inflammatory bowel disease.
    • Myocardial Infarction (Heart Attack):
      • Early Post-MI Pericarditis: Occurs within a few days of a heart attack due to inflammation from myocardial necrosis.
      • Dressler's Syndrome (Post-cardiac Injury Syndrome): An autoimmune reaction occurring weeks to months after a heart attack, cardiac surgery, or trauma.
    • Uremia: Occurs in patients with kidney failure due to the buildup of toxins (uremic pericarditis).
    • Malignancy: Cancer spreading to the pericardium (e.g., lung cancer, breast cancer, lymphoma).
    • Trauma: Injury to the chest or heart, including iatrogenic (due to medical procedures).
    • Radiation Therapy: Can lead to acute or chronic pericarditis.
    • Drugs: Certain medications (e.g., procainamide, hydralazine, isoniazid) can induce drug-induced lupus-like syndromes with pericardial involvement.
    • Metabolic Disorders: Hypothyroidism (myxedema).
    According to Culprit
    Infectious Pericarditis

    Infections are a common cause, particularly viral, leading to acute pericarditis. Other pathogens are less frequent but can cause more severe disease.

  • Viral: This is the most common cause of acute pericarditis. Viruses directly infect and inflame the pericardium.
    • Common culprits: Coxsackievirus B (most frequent), Adenovirus, Echovirus, Influenza virus (A and B), Parvovirus B19, Herpesviruses (CMV, EBV, VZV), HIV.
    • Mechanism: Direct viral invasion and replication within pericardial cells, triggering an inflammatory response.
  • Bacterial: Less common in developed countries due to widespread antibiotic use, but can be severe, often leading to purulent (pus-filled) pericarditis.
    • Pyogenic (Pus-forming) Bacteria: Staphylococcus aureus, Streptococcus pneumoniae (Pneumococci), other Streptococci.
    • Routes of Infection: Hematogenous spread (from bloodstream, e.g., septicemia), direct extension from adjacent infections (e.g., pneumonia, empyema), or direct inoculation (e.g., cardiac surgery, trauma).
    • Tuberculosis (TB): A significant cause in endemic areas. Tuberculous pericarditis can lead to chronic, constrictive pericarditis.
  • Fungal: Rare, typically seen in immunocompromised individuals.
    • Examples: Histoplasma capsulatum, Candida species, Aspergillus.
  • Parasitic: Extremely rare in most regions, but important in specific geographic areas.
    • Example: Toxoplasma gondii, Entamoeba histolytica (amoebic pericarditis), Echinococcus (hydatid cyst).
  • Non-Infectious Pericarditis

    A significant proportion of pericarditis cases are not caused by direct infection but rather by systemic conditions, injury, or other inflammatory processes.

  • Autoimmune/Inflammatory Diseases: Conditions where the immune system mistakenly attacks the body's own tissues.
    • Systemic Lupus Erythematosus (SLE): Pericarditis is a common manifestation of lupus.
    • Rheumatoid Arthritis (RA): Less common, but can cause pericardial involvement.
    • Scleroderma (Systemic Sclerosis): Can lead to pericardial effusion and thickening.
    • Ankylosing Spondylitis: A chronic inflammatory disease primarily affecting the spine, but can have cardiac manifestations.
    • Inflammatory Bowel Disease (IBD): (Crohn's disease, Ulcerative colitis) can have extra-intestinal manifestations, including pericarditis.
    • Rheumatic Fever: An inflammatory disease that can develop as a complication of untreated streptococcal infection, affecting the heart (rheumatic carditis), joints, brain, and skin. Pericarditis is one component of carditis.
  • Post-Cardiac Injury Syndromes: Inflammatory reactions following damage to the heart or pericardium.
    • Dressler's Syndrome (Post-Myocardial Infarction Syndrome): An immune-mediated inflammation of the pericardium that occurs weeks to months after a myocardial infarction (heart attack).
    • Post-Pericardiotomy Syndrome (PPS): Occurs after cardiac surgery (e.g., bypass surgery, valve replacement, pacemaker insertion) due to inflammation from surgical trauma.
  • Trauma: Direct chest trauma (e.g., blunt force, penetrating injuries) can cause pericardial injury and inflammation.
  • Metabolic Disorders:
    • Uremia: Occurs in patients with severe kidney failure (end-stage renal disease) due to the accumulation of metabolic toxins that irritate the pericardium. It typically does not respond to anti-inflammatory drugs and requires dialysis.
    • Myxedema (Severe Hypothyroidism): Can lead to pericardial effusion due to increased capillary permeability and fluid retention.
  • Malignancy (Cancer):
    • Metastatic Cancer: Cancer cells can spread to the pericardium from primary tumors (e.g., lung cancer, breast cancer, lymphoma, leukemia, melanoma). This often leads to malignant pericardial effusion.
    • Primary Pericardial Tumors: Very rare (e.g., mesothelioma).
  • Radiation-Induced Pericarditis: Can occur as a complication of radiation therapy to the chest for cancer treatment (e.g., breast cancer, Hodgkin's lymphoma). Can manifest acutely or years after treatment.
  • Acute Myocardial Infarction (MI): Early pericarditis can occur in the first few days after a transmural (ST-elevation) MI due to inflammation over the necrotic myocardial tissue.
  • Aortic Dissection: If an aortic dissection extends into the pericardial sac, it can cause hemopericardium (blood in the pericardial sac) and acute pericarditis-like pain. This is a medical emergency.
  • Drug-Induced Pericarditis: Certain medications can trigger a lupus-like syndrome or direct pericardial inflammation.
    • Examples: Isoniazid, Procainamide, Hydralazine, Phenytoin, Minoxidil, Cyclosporine, Anthracyclines (some chemotherapy drugs).
  • Idiopathic Pericarditis: When no specific cause can be identified despite thorough investigation, it is termed idiopathic. This is the most common diagnosis for acute pericarditis, often presumed to be viral.
  • Pathophysiology of Pericarditis

    The acute inflammatory response in pericardium can produce either serous or purulent fluid, or a dense fibrinous material. In viral pericarditis, the pericardial fluid is most commonly serous, is of low volume, and resolves spontaneously.

    Neoplastic, tuberculous, and purulent pericarditis may be associated with large effusions that are exudative, hemorrhagic, and leukocyte filled.

    Gradual accumulation of large fluid volumes in the pericardium, even up to 250 mL, may not result in significant clinical signs.

    Clinical Manifestations of Pericarditis

    Beck's triad is a collection of three medical signs associated with acute cardiac tamponade. The signs are:

    • Low arterial blood pressure
    • Distended neck veins
    • Distant, muffled heart sounds.

    Chest pain symptoms associated with pericarditis can be described as:

    • Sharp and stabbing chest pain (caused by the heart rubbing against the pericardium). May increase with coughing, deep breathing or lying flat.
    • Can be relieved by sitting up and leaning forward.
    • You may also feel the need to bend over or hold your chest to breathe more comfortably.
    Other clinical features include;

    The symptoms of pericarditis can range from mild to severe and may mimic other cardiac conditions. The classic symptoms include:

  • Chest Pain:
    • Character: Typically sharp, stabbing, or pleuritic (worsens with deep breath, cough, or swallowing). Can also be dull, aching, or pressure-like.
    • Location: Usually substernal (behind the breastbone) or precordial (over the heart), often radiating to the left shoulder, neck, trapezius ridge (shoulder blade area), or back.
    • Aggravating Factors: Worsens with lying flat (supine position), deep inspiration, coughing, swallowing, and sometimes with movement.
    • Relieving Factors: Often eased by sitting up and leaning forward. This position reduces pressure on the inflamed pericardium.
  • Pericardial Friction Rub: A characteristic scratching, grating, or squeaking sound heard during auscultation of the heart, caused by the inflamed pericardial layers rubbing against each other. It is best heard with the diaphragm of the stethoscope over the left sternal border, with the patient leaning forward and exhaling. This is a highly specific sign.
  • Dyspnoea (Shortness of Breath): May be due to pleuritic chest pain limiting deep breaths, or in severe cases, due to pericardial effusion leading to cardiac tamponade.
  • Low-Grade Fever: Common, especially in infectious causes.
  • Fatigue and Malaise: Generalized symptoms due to the inflammatory process.
  • Palpitations: Can occur if the inflammation irritates the heart muscle or conductive system.
  • Cough: May be present due to irritation of the airways or associated pleural inflammation.
  • Anxiety: Often results from the frightening nature of chest pain and other symptoms.
  • Cardinal Signs and Symptoms of Pericarditis (Mnemonics)

    Remember “Friction” (as previously noted) and also consider the more comprehensive "PERICARDITIS" mnemonic for key features:

    • Friction rub pericardial (sounds like a grating, scratching sound), Fever
    • Radiating substernal pain to left shoulder, neck or back
    • Increased pain when in supine position (leaning forward relieves pain)
    • Chest pain that is stabbing (will feel like a heart attack)
    • Trouble breathing when lying down (supine position)
    • Inspiration or coughing makes pain worse
    • Overall feels very sick and weak
    • Noticeable ST segment elevation on ECG (often widespread concave up)
    P.E.R.I.C.A.R.D.I.T.I.S. Mnemonic:
    • Pleuritic chest pain (worsens with breathing)
    • ECG changes (widespread ST elevation, PR depression)
    • Rub (pericardial friction rub)
    • Increased pain with supine position
    • Cough, fever, malaise (flu-like symptoms)
    • Autoimmune disease history
    • Radiation to trapezius ridge (classic finding)
    • Difficulty breathing (dyspnoea)
    • Increased pain with inspiration
    • Treatment with NSAIDs (often effective)
    • Idiopathic or Infectious cause (viral most common)
    • Sitting up and leaning forward relieves pain
    Types of Pericarditis

    Pericarditis is classified based on its temporal course and characteristics:

  • Acute Pericarditis:
    • Onset: Sudden and rapid.
    • Duration: Typically resolves within 3 weeks.
    • Characteristics: Often associated with severe chest pain and a pericardial friction rub. Usually self-limiting, but can recur.
    • Common Causes: Viral infections, idiopathic.
  • Incessant Pericarditis:
    • Duration: Lasts for more than 4-6 weeks but less than 3 months, with continuous presence of symptoms and signs without remission.
    • Characteristics: Symptoms persist despite initial treatment, indicating ongoing inflammation.
  • Recurrent Pericarditis:
    • Onset: Occurs after a symptom-free interval of at least 4-6 weeks following an acute episode.
    • Characteristics: Can be very distressing for patients, with repeated episodes of chest pain and inflammation. Often requires long-term management.
    • Causes: Often idiopathic, but can be associated with autoimmune conditions.
  • Chronic Pericarditis:
    • Duration: Develops slowly and lasts for more than 3 months.
    • Characteristics: Can lead to pericardial thickening and fibrosis, potentially progressing to more serious conditions like constrictive pericarditis. Symptoms may be less acute but persistent.
  • Constrictive Pericarditis:
    • Nature: A serious complication of chronic pericarditis where the pericardium becomes thick, rigid, and fibrotic.
    • Mechanism: This hardened sac restricts the heart's ability to expand and fill with blood properly during diastole.
    • Consequences: Leads to impaired cardiac filling, elevated venous pressures, and symptoms of right-sided heart failure (e.g., severe edema, ascites, jugular venous distension).
  • Investigations for Pericarditis

    Diagnosing pericarditis involves a combination of clinical assessment, specific tests to confirm inflammation, identify the cause, and assess for complications.

    Medical History and Physical Exam:
  • History: Detailed inquiry about chest pain characteristics (onset, location, radiation, aggravating/relieving factors), fever, recent infections, autoimmune conditions, trauma, medications, and travel history.
  • Physical Exam:
    • Pericardial Friction Rub: The hallmark sign, a scratching or squeaking sound best heard with the diaphragm of the stethoscope over the left sternal border, with the patient leaning forward and holding their breath in expiration.
    • Signs of Pericardial Effusion/Tamponade: Muffled heart sounds, pulsus paradoxus, jugular venous distension, hypotension (late signs).
    • Signs of Systemic Disease: Rash, joint swelling (suggesting autoimmune disease).
  • Diagnostic Tests
  • Electrocardiography (ECG):
    • Classic Findings: Widespread ST-segment elevation (concave upwards) in most leads (unlike MI, which is localized and convex), and PR-segment depression (especially in leads II, aVF, V5, V6). These changes reflect inflammation of the epicardium.
    • Evolution: ECG changes typically evolve over days to weeks, from ST elevation to T-wave inversion, then normalization.
  • Echocardiography (Echo):
    • Purpose: The most important imaging test. It is essential for assessing for pericardial effusion (fluid around the heart) and its hemodynamic significance (e.g., signs of cardiac tamponade).
    • Information Provided: Can visualize the pericardium, quantify effusion size, assess cardiac chamber size and function, and identify signs of cardiac tamponade (e.g., right ventricular diastolic collapse, paradoxical septal motion).
  • Cardiac CT scan/MRI:
    • Cardiac Computed Tomography (CT): Useful for visualizing pericardial thickening, calcification (in constrictive pericarditis), and large effusions. Can help differentiate pericardial disease from myocardial disease.
    • Cardiovascular Magnetic Resonance Imaging (MRI): Provides excellent soft tissue characterization. It is the gold standard for detecting pericardial inflammation, edema, and fibrosis. Can also differentiate constrictive pericarditis from restrictive cardiomyopathy.
  • Blood Tests:
    • Inflammatory Markers: C-reactive protein (CRP) and Erythcyte Sedimentation Rate (ESR) are usually elevated.
    • Cardiac Biomarkers: Troponin (I or T) may be mildly elevated in myopericarditis. CK-MB and Myoglobin may be checked.
    • Infectious Workup: Viral Serology, Bacterial Cultures (blood/fluid), TB Tests (PPD, IGRAs, AFB stains).
    • Autoimmune Markers: ANA, RF, Anti-dsDNA if autoimmune disease is suspected.
    • Renal Function Tests: BUN and Creatinine to assess for uremia.
  • Radionuclide Scanning (e.g., PET scan): May be used in complex cases to detect areas of active inflammation or malignancy, particularly if other tests are inconclusive.
  • Pericardiocentesis and Pericardial Biopsy:
    • Pericardiocentesis: A procedure to drain fluid from the pericardial sac. Indicated for large effusions, signs of cardiac tamponade, or for diagnostic purposes.
    • Pericardial Biopsy: Rarely performed, but may be considered in cases of chronic or recurrent pericarditis with an unknown etiology.
  • Nursing Interventions and Management of Pericarditis

    Nursing care for patients with pericarditis focuses on pain management, monitoring for complications, providing emotional support, and patient education.

    General Principles of Management
  • Goal: Relieve pain, reduce inflammation, prevent complications (e.g., cardiac tamponade, constrictive pericarditis), and treat the underlying cause.
  • Setting: Mild cases may be managed outpatient, while moderate to severe cases, or those with complications, require hospitalization.
  • Management for Mild Pericarditis

    Patients with mild, uncomplicated pericarditis often respond well to conservative measures and oral medications.

  • Pain Assessment and Management:
    • Assess Patient’s Pain: Characterize the pain (sharp, stabbing, dull), location, radiation, and aggravating/relieving factors. Use a pain scale (e.g., 0-10) to quantify severity. Pericarditis pain can be excruciatingly painful.
    • Positioning for Pain Relief: Keep patient in a high Fowler’s position (sitting upright) or encourage leaning forward. Avoid a supine (lying flat) position, as it exacerbates pericardial pain by increasing pressure on the inflamed pericardium.
  • Monitoring for Complications (e.g., Cardiac Tamponade):
    • Constant Vigilance: Cardiac tamponade is a life-threatening complication that requires immediate recognition and intervention.
    • Key Signs to Monitor (Beck's Triad): Muffled or Distant Heart Sounds, Jugular Venous Distension (JVD) with Clear Lungs, Hypotension.
    • Other Signs: Pulsus Paradoxus, Tachycardia, narrowed pulse pressure, decreased urine output, cool extremities, altered mental status.
  • Administer Medications as Prescribed by Physician:
    • High-dose Aspirin: Often used, especially for post-MI pericarditis.
    • NSAIDs (e.g., Ibuprofen, Indomethacin): The cornerstone of treatment for acute pericarditis. Administer with food/milk. Monitor for GI bleeding.
    • Colchicine: An anti-inflammatory agent increasingly used as first-line therapy or in combination with NSAIDs. Do not take with grapefruit juice.
    • Corticosteroids (e.g., Prednisone): Reserved for patients who do not respond to NSAIDs/Colchicine or have specific etiologies. Taper slowly.
    • IV Antibiotics: Administered if bacterial pericarditis is diagnosed or strongly suspected.
  • Management for Moderate to Severe Pericarditis / Hospitalized Patients

    These patients require more intensive monitoring and often invasive procedures.

    • Comprehensive Assessment: Establish good rapport, take detailed history, and perform continuous observations of vital signs.
    • Pain Management Intensified: Continue positioning for relief, monitor pain levels continuously, and administer stronger analgesics (e.g., morphine) if needed.
    • Intensive Cardiac Monitoring: Hourly assessment for cardiac tamponade signs and continuous ECG monitoring.
    • Fluid Balance and Hemodynamic Support: Careful maintenance of I&O, daily weight checks, oxygen administration to maintain SpO2 >90%, and IV antihypertensives if needed.
    • Medication Administration and Monitoring: Administer meds with food to reduce GI side effects and ensure timely antibiotics if bacterial.
    • Patient Education and Psychological Support: Discuss disease process, reduce anxiety, prepare for procedures, educate on post-surgical care and activity progression, and teach warning signs for home.
    • Bowel and Bladder Care: Provide bedside commode and assist with bathing to conserve energy.
    • Monitoring for Specific Complications: Closely monitor for persistent cough, vomiting, or systolic BP >180 mmHg.
    Specific Nursing Interventions (Procedure Table)
    Intervention Category Action & Rationale/Detail
    Pain Management and Comfort Assess pain level regularly using a standardized scale. Evaluate effectiveness of analgesics within 30-60 mins. Administer meds promptly. Position patient in high Fowler's or leaning forward (avoid supine). Provide non-pharmacological relief (guided imagery, distraction).
    Vital Signs and Hemodynamic Monitoring Monitor vitals frequently. Continuously monitor ECG for ST-T changes. Assess for signs of cardiac tamponade (muffled sounds, JVD, hypotension, pulsus paradoxus) every 4-8 hours or PRN. Monitor for signs of decreased cardiac output. Administer O2 to maintain SpO2 > 90%.
    Medication Administration and Monitoring Administer NSAIDs/Corticosteroids with food/milk to minimize GI irritation. Educate on side effects. Monitor for adverse effects (GI bleeding, hyperglycemia, diarrhea). Ensure timely antibiotic administration if prescribed.
    Fluid Balance and Nutritional Support Maintain accurate I&O records. Monitor daily weights. Encourage oral fluids unless contraindicated. Provide easily digestible diet. Assist with feeding if fatigued.
    Activity and Rest Ensure bed rest during acute phase (until fever/pain/rub resolve). Assist with ADLs. Provide bedside commode to reduce straining. Educate on gradual return to activity.
    Patient Education and Psychological Support Explain disease process and treatment. Reassure that pain is likely not an MI. Build rapport. Provide psychological support. Explain procedures (e.g., pericardiocentesis). Educate on warning signs of recurrence or complications. Discuss medication adherence.
    Monitoring for Other Complications Monitor for persistent cough, vomiting, or systolic BP >180 mmHg. Assess for signs of chronic/constrictive pericarditis (persistent JVD, ascites, edema).
    Nursing Diagnoses for Pericarditis
    Acute Pain
    • Related to: Inflammatory process of the pericardium.
    • As evidenced by: Verbalization of severe chest pain ("10 out of 10", sharp, stabbing), facial grimacing, guarding, restlessness, increased HR/BP, pain exacerbated by breathing/coughing/lying supine, pain relieved by leaning forward.
    Rationale: The hallmark of acute pericarditis is severe, often pleuritic, chest pain caused by the inflammation and irritation of the pericardial layers. This pain significantly impacts comfort and can trigger sympathetic responses.
    Hyperthermia
    • Related to: Inflammatory process (e.g., infection, autoimmune response).
    • As evidenced by: Body temp > 38.0°C, flushed skin, warm to touch, increased HR/RR, sweating/chills, malaise.
    Rationale: Inflammation, particularly if infectious, often leads to a systemic febrile response as the body attempts to combat the underlying cause and inflammatory mediators are released.
    Decreased Cardiac Output
    • Related to: Impaired ventricular filling due to pericardial inflammation and/or effusion.
    • As evidenced by: Fatigue, weakness, inability to perform ADLs, shortness of breath, tachycardia, hypotension, weak pulses, cool skin, delayed capillary refill, decreased urine output, altered mental status, abnormal hemodynamics.
    Rationale: Inflammation of the pericardium can lead to fluid accumulation (effusion) or thickening/constriction, both of which can impede the heart's ability to fill adequately, thereby reducing the amount of blood pumped out to the body.
    Activity Intolerance
    • Related to: Acute chest pain, decreased cardiac output, and systemic inflammation.
    • As evidenced by: Verbalization of fatigue/weakness after exertion, dyspnea on exertion, disinterest in ADLs, need for increased rest, changes in vitals with activity.
    Rationale: The pain associated with pericarditis makes movement difficult, and the systemic inflammatory response, coupled with potentially decreased cardiac output, reduces the patient's physiological reserve for physical activity.
    Excessive Anxiety
    • Related to: Chest pain of unknown etiology, fear of serious cardiac event (e.g., heart attack), threat to health status.
    • As evidenced by: Verbalization of fear/worry, increased HR/RR, restlessness, crying, sleep disturbances, questioning prognosis.
    Rationale: Chest pain is often associated with myocardial infarction, leading to significant anxiety for patients. The uncertainty of the diagnosis, the severity of symptoms, and the potential for complications can further exacerbate anxiety.
    Risk for Ineffective Health Management
    • Related to: Insufficient knowledge of the disease process, treatment regimen, and potential for recurrence.
    Rationale: Patients need comprehensive education on their condition, medications, symptom recognition, and activity modifications to prevent recurrence and manage the disease effectively post-discharge.
    Risk for Fluid Volume Deficit
    • Related to: Fever-induced diaphoresis, nausea/vomiting impacting oral intake, aggressive diuretic therapy.
    Rationale: While fluid overload is a concern with effusions, certain interventions or symptoms can lead to dehydration, necessitating careful fluid balance monitoring.
    Risk for Impaired Gas Exchange
    • Related to: Decreased lung expansion due to large pericardial effusion, reduced cardiac output impacting pulmonary perfusion.
    Rationale: A very large effusion can restrict lung expansion, and severe cardiac compromise can lead to ventilation-perfusion mismatch.
    Risk for Infection (post-procedural)
    • Related to: Invasive procedures (e.g., pericardiocentesis, pericardiectomy).
    • As evidenced by: Surgical incision/puncture site, disruption of skin integrity, invasive lines.
    Rationale: Any break in skin integrity or invasive procedure introduces a risk of localized or systemic infection.
    Complications of Pericarditis

    While most cases of acute pericarditis are benign and self-limiting, complications can occur, ranging from mild to life-threatening.

    • Pericardial Effusion: Accumulation of excess fluid within the pericardial sac. Can range from small to large and rapidly accumulating.
    • Cardiac Tamponade: A medical emergency where a large or rapidly accumulating effusion compresses the heart, restricting filling. Leads to decreased cardiac output, hypotension, and shock. Requires urgent drainage.
    • Recurrent Pericarditis: Episodes recur after a symptom-free interval. Often requires long-term anti-inflammatory therapy.
    • Chronic Pericarditis: Persists > 3 months. Can lead to thickening/fibrosis.
    • Constrictive Pericarditis: Severe, long-term complication where the pericardium becomes thick, rigid, and fibrotic, preventing proper filling. Causes right-sided heart failure symptoms. Treatment often requires pericardiectomy.
    • Myocarditis (Myopericarditis): Inflammation of the heart muscle occurring concurrently. Can lead to myocardial dysfunction and arrhythmias.
    • Fatal Hemorrhage: Rare but catastrophic, associated with trauma, iatrogenic injury, or vessel rupture.
    • Stroke/Paraplegia/Abdominal Ischemia: Severe complications specifically associated with Aortic Dissection if it involves great vessels or spinal/abdominal blood supply. If dissection causes hemopericardium, it mimics pericarditis but requires different emergency management.

    Pericarditis Read More »

    Want notes in PDF? Join our classes!!

    Send us a message on WhatsApp
    0726113908

    Scroll to Top
    Enable Notifications OK No thanks